NZ622215B2 - Solid forms of (1,1-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone - Google Patents
Solid forms of (1,1-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone Download PDFInfo
- Publication number
- NZ622215B2 NZ622215B2 NZ622215A NZ62221512A NZ622215B2 NZ 622215 B2 NZ622215 B2 NZ 622215B2 NZ 622215 A NZ622215 A NZ 622215A NZ 62221512 A NZ62221512 A NZ 62221512A NZ 622215 B2 NZ622215 B2 NZ 622215B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- disorders
- disorder
- solid form
- formula
- xrpd
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 108
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 title abstract 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 87
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 201000010099 disease Diseases 0.000 claims abstract description 56
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 22
- 206010061920 Psychotic disease Diseases 0.000 claims abstract description 19
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 19
- 230000001154 acute Effects 0.000 claims abstract description 18
- 208000006011 Stroke Diseases 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 230000019771 cognition Effects 0.000 claims abstract description 13
- 206010012289 Dementia Diseases 0.000 claims abstract description 11
- 201000010374 Down syndrome Diseases 0.000 claims abstract description 11
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims abstract description 11
- 206010001897 Alzheimer's disease Diseases 0.000 claims abstract description 10
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims abstract description 9
- 206010057666 Anxiety disease Diseases 0.000 claims abstract description 9
- 206010003805 Autism Diseases 0.000 claims abstract description 9
- 206010013663 Drug dependence Diseases 0.000 claims abstract description 9
- 206010016845 Foetal alcohol syndrome Diseases 0.000 claims abstract description 9
- 206010027175 Memory impairment Diseases 0.000 claims abstract description 9
- 208000004296 Neuralgia Diseases 0.000 claims abstract description 9
- 206010033666 Panic disease Diseases 0.000 claims abstract description 9
- 208000005793 Restless Legs Syndrome Diseases 0.000 claims abstract description 9
- 208000004490 Stress Disorders, Traumatic, Acute Diseases 0.000 claims abstract description 9
- 201000005913 acute stress disease Diseases 0.000 claims abstract description 9
- 201000002055 autistic disease Diseases 0.000 claims abstract description 9
- 230000035591 circadian rhythms Effects 0.000 claims abstract description 9
- 201000007794 fetal alcohol syndrome Diseases 0.000 claims abstract description 9
- 201000009906 meningitis Diseases 0.000 claims abstract description 9
- 201000008895 mood disease Diseases 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 206010012256 Delusional disease Diseases 0.000 claims abstract description 8
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims abstract description 8
- 206010040984 Sleep disease Diseases 0.000 claims abstract description 8
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims abstract description 7
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 7
- 206010004938 Bipolar disease Diseases 0.000 claims abstract description 7
- 206010057668 Cognitive disease Diseases 0.000 claims abstract description 7
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims abstract description 7
- 206010072388 Substance-induced psychotic disease Diseases 0.000 claims abstract description 7
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims abstract description 7
- 230000001684 chronic Effects 0.000 claims abstract description 7
- 201000009457 movement disease Diseases 0.000 claims abstract description 7
- 239000000546 pharmaceutic aid Substances 0.000 claims abstract description 7
- 238000011084 recovery Methods 0.000 claims abstract description 7
- 206010018075 Generalised anxiety disease Diseases 0.000 claims abstract description 6
- 206010061536 Parkinson's disease Diseases 0.000 claims abstract description 6
- 201000006529 generalized anxiety disease Diseases 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- 208000009025 Nervous System Disease Diseases 0.000 claims abstract description 5
- 206010029305 Neurological disorder Diseases 0.000 claims abstract description 5
- 239000002475 cognitive enhancer Substances 0.000 claims abstract description 4
- 239000002664 nootropic agent Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 122
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 104
- 239000000203 mixture Substances 0.000 claims description 67
- 239000000243 solution Substances 0.000 claims description 53
- 239000002904 solvent Substances 0.000 claims description 39
- 239000000725 suspension Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 32
- 238000004090 dissolution Methods 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 21
- 239000012296 anti-solvent Substances 0.000 claims description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 238000010899 nucleation Methods 0.000 claims description 8
- 241000229754 Iva xanthiifolia Species 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 229960004592 isopropanol Drugs 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000000926 neurological Effects 0.000 claims description 2
- 241001669679 Eleotris Species 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 abstract description 10
- 238000010438 heat treatment Methods 0.000 abstract description 6
- 229950006259 Basmisanil Drugs 0.000 abstract 5
- 229910016519 CuK Inorganic materials 0.000 abstract 2
- -1 4- FLUOROPHENYL Chemical class 0.000 description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- GDSRMADSINPKSL-HSEONFRVSA-N γ-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 48
- 239000008186 active pharmaceutical agent Substances 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 230000002829 reduced Effects 0.000 description 23
- 229920000858 Cyclodextrin Polymers 0.000 description 22
- 150000002500 ions Chemical class 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 14
- 238000001237 Raman spectrum Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical group 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 125000004429 atoms Chemical group 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 239000011521 glass Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000001965 increased Effects 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229960003692 aminobutyric acid Drugs 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 125000005842 heteroatoms Chemical group 0.000 description 7
- RHQDFWAXVIIEBN-UHFFFAOYSA-N 2,2,2-trifluoroethyl alcohol Chemical group OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 6
- 238000001069 Raman spectroscopy Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000005712 crystallization Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 150000004682 monohydrates Chemical group 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- JYVLIDXNZAXMDK-UHFFFAOYSA-N 2-Pentanol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- 229940097362 Cyclodextrins Drugs 0.000 description 4
- JGZXSHPSEVOQCV-UHFFFAOYSA-N FC1=CC=C(C=C1)CC1=NOC=C1CO Chemical compound FC1=CC=C(C=C1)CC1=NOC=C1CO JGZXSHPSEVOQCV-UHFFFAOYSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910052904 quartz Inorganic materials 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- 238000004450 types of analysis Methods 0.000 description 4
- YPVOCNRPBFPDLO-UITAMQMPSA-N (NZ)-N-[(2-fluorophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC=C1F YPVOCNRPBFPDLO-UITAMQMPSA-N 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000035514 bioavailability Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 3
- 229910052738 indium Inorganic materials 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000010591 solubility diagram Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- RYFCDAXBGQWNIC-YFHOEESVSA-N (1Z)-2-fluoro-N-hydroxybenzenecarboximidoyl chloride Chemical compound O\N=C(/Cl)C1=CC=CC=C1F RYFCDAXBGQWNIC-YFHOEESVSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 230000035536 Oral bioavailability Effects 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001149 cognitive Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- CLUPOLFGIGLMIQ-UHFFFAOYSA-N heptane;propan-2-ol Chemical compound CC(C)O.CCCCCCC CLUPOLFGIGLMIQ-UHFFFAOYSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000036220 oral bioavailability Effects 0.000 description 2
- 230000002572 peristaltic Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000010935 polish filtration Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- GTIIVHODSNYECK-UHFFFAOYSA-N 1,1,1-trifluoropropane Chemical group [CH2]CC(F)(F)F GTIIVHODSNYECK-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- RYFCDAXBGQWNIC-UHFFFAOYSA-N 2-fluoro-N-hydroxybenzenecarboximidoyl chloride Chemical compound ON=C(Cl)C1=CC=CC=C1F RYFCDAXBGQWNIC-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- ORIQLMBUPMABDV-UHFFFAOYSA-N 6-chloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C=N1 ORIQLMBUPMABDV-UHFFFAOYSA-N 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 102100005985 DSC1 Human genes 0.000 description 1
- 108060002385 DSC3 Proteins 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 1
- FSKSLWXDUJVTHE-UHFFFAOYSA-N N-[(4-fluorophenyl)methylidene]hydroxylamine Chemical compound ON=CC1=CC=C(F)C=C1 FSKSLWXDUJVTHE-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 108060007738 NaCP60E Proteins 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 238000010928 TGA analysis Methods 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001066 destructive Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UMYZHWLYICNGRQ-UHFFFAOYSA-N ethanol;heptane Chemical compound CCO.CCCCCCC UMYZHWLYICNGRQ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000003371 gabaergic Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052699 polonium Inorganic materials 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 101700082413 tant Proteins 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001845 vibrational spectrum Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Disclosed is anhydrous polymorphic form C of basmisanil ((1,1-dioxo-thiomorpholin-4-yl)-(6-{[3-(4-fluorophenyl)-5-methyl-isoxazol-4-yl]methoxy}-pyridin-3-yl)-methanone / RG-1662 / RO5186582 / (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone) as represented by formula (I), characterized by an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta (CuK?) of 11.7°±0.2°, 17.4°±0.2° and 23.4°±0.2°. Polymorphic form C of basmisanil can also be characterised by a melting point with onset temperature (DSC) in the range of about 146 °C to 150 °C (heating rate of 10°C/min.). Also disclosed is a pharmaceutical compositions comprising a solid crystalline form of a compound of basmisanil as defined above and a pharmaceutically acceptable excipient, for the treatment or prevention of acute and/or chronic neurological disorders, cognitive disorders, Alzheimer’s disease, memory deficits, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, bipolar disorders, autism, Down syndrome, neurofibromatosis type I, sleep disorders, disorders of circadian rhythms, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, psychotic disorders, substance-induced psychotic disorder, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive/compulsive disorders, acute stress disorder, drug addictions, movement disorders, Parkinson’s disease, restless leg syndrome, cognition deficiency disorders, multi-infarct dementia, mood disorders, depression, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, neuropathic pain, stroke, Multiple Sclerosis (MS), acute Meningitis, Fetal Alcohol Syndrome, and attentional disorders, for stroke recovery therapy, or for use as cognitive enhancers. ne) as represented by formula (I), characterized by an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta (CuK?) of 11.7°±0.2°, 17.4°±0.2° and 23.4°±0.2°. Polymorphic form C of basmisanil can also be characterised by a melting point with onset temperature (DSC) in the range of about 146 °C to 150 °C (heating rate of 10°C/min.). Also disclosed is a pharmaceutical compositions comprising a solid crystalline form of a compound of basmisanil as defined above and a pharmaceutically acceptable excipient, for the treatment or prevention of acute and/or chronic neurological disorders, cognitive disorders, Alzheimer’s disease, memory deficits, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, bipolar disorders, autism, Down syndrome, neurofibromatosis type I, sleep disorders, disorders of circadian rhythms, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, psychotic disorders, substance-induced psychotic disorder, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive/compulsive disorders, acute stress disorder, drug addictions, movement disorders, Parkinson’s disease, restless leg syndrome, cognition deficiency disorders, multi-infarct dementia, mood disorders, depression, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, neuropathic pain, stroke, Multiple Sclerosis (MS), acute Meningitis, Fetal Alcohol Syndrome, and attentional disorders, for stroke recovery therapy, or for use as cognitive enhancers.
Description
Case 27305
SOLID FORMS OF IOXOTHIOMORPHOLINYL)-[6-[[3(4-
FLUOROPHENYL)METHYLISOXAZOLYL]METHOXY]PYRIDINYL]-
METHANONE
The instant invention relates to novel solid forms of nds of formula (I)
N S
N O
F (I),
as well as processes for their cture, pharmaceutical compositions containing these
solid forms, and their use as medicaments.
Background of the ion
Polymorphism is the ability of a compound to crystallize as more than one distinct crystal
species. Different polymorphic forms (or polymorphs) have different arrangements or
mations of the les in the crystal lattice. If a solid does not possess a distinguishable
crystal lattice and the molecular arrangement of molecules is disordered, it is considered
amorphous. The amorphous state is structurally r to the liquid state [W. McCrone, Phys.
Chem. Org. Solid State (1965) 2:725767].
Polymorphic forms of a drug substance can have different chemical, physical and
physicotechnical properties. Differences can result from e.g. packing of molecules in the crystal
structure (density, refractive index, conductivity, hygroscopicity), thermodynamic properties
(melting point, heat capacity, vapor pressure, solubility), c properties (dissolution rate,
stability), surface properties ce free energy, interfacial tension, shape, morphology), and
mechanical properties (compactibility, tensile strength). These properties can have a direct effect
on the y to process and manufacture the active pharmaceutical ingredient (API) and the
drug product. Polymorphism further has pharmacological implications due to altered solid state
properties and suitability for a particular formulation. Thus, polymorphism of an API can affect
the quality, safety, efficacy and developability of a drug product and is therefore of fundamental
importance [D. Giron et al., J. Therm. Anal. Cal. (2004) 77:709].
THR / 21.08.2012
In addition to rphic modifications, an API can be crystallized in different salt forms
with an appropriate counterion. Similar to polymorphism, salt forms are varying from each other
in the degree of solubility and many other physical and chemical factors, as denoted above. As
compared to the free acid or free base of the API, an appropriate salt form might provide
improved aqueous solubility, dissolution rate, hygroscopicity, chemical stability, g point,
or mechanical properties.
Solvates, also known as pseudopolymorphs, are l forms having either stoichiometric
or nonstoichiometric amounts of a solvent incorporated in the crystal lattice. If the incorporated
solvent is water, the solvate is commonly known as a hydrate.
Salts and inclusion complexes both are omponent systems. Salts are formed by ionic
bonding ctions with complete proton transfer between acid and base whereas in inclusion
complexes the molecules are neutral in the lline state and are connected mainly through
hydrogen bonds or Van der Waals interactions [S.L. Morissette et al., Adv. Drug Del. Rev. (2004)
56:275-300].
Cyclodextrins are sed of six, seven, or eight glucose units, tively, and have
hydrophilic cavity exteriors and hydrophobic cavity interiors [V.J. Stella et al., Adv. Drug Del.
Rev. (2007) 59:677-694]. These properties are responsible for their aqueous solubility and ability
to incorporate hydrophobic molecular moieties within their cavities. Cyclodextrins can be
employed as inclusion complex s for ion complexes with APIs, in which the API is
trapped by a cavity of cyclodextrin molecules. It is reported in the literature that the crystal
structures of cyclodextrin inclusion complexes are typically dominated by the spatial
arrangement of the host molecules. Thereby the cyclodextrin may form a defined packing
arrangement similar to a crystalline state, whereas the API does not occupy well defined lattice
positions [T. Uyar et al., Cryst. Growth Des. (2006) 6:1113-1119, T. Toropainen et al., Pharm.
Res. (2007) 24:1058-1066].
Among the commercially available cyclodextrins, γ-cyclodextrin (γ-CD) is reported to be
stable and has been found safe for oral administration [I.C. Munro et al., Regulatory Toxicology
and Pharmacology (2004) 39:S3-S13]. However, γ-cyclodextrins are not used in marketed drug
preparations up to now. A monograph has only recently (12/2008) been included in the European
pharmacopoeia. The formation of inclusion xes with cyclodextrins is not predictable and
needs comprehensive experimental investigation. In those cases where inclusion xes with
γ-cyclodextrin are , most active pharmaceutical ingredients form a 2:1 x (ratio
between inclusion x former and API). The formation of cyclodextrin inclusion complexes
and their guest to host stoichiometries are highly dependent on the molecular structures and the
geometrical sizes of the guest molecules [T. Uyar et al., Cryst. Growth Des. (2006) 6:1113-
1119].
The compound of formula (I), its manufacture, its pharmacological activity as inverse
agonists of the GABA A α5 receptor, and its use for the treatment, prevention and/or delay of
progression of various central s system (CNS) conditions have been described in WO
2009/071476. Based on its physicochemical properties, the compound of formula (I), as
bed in WO 71476, is a BCS 2 compound, exhibiting low aqueous solubility and
high permeability, according to the biopharmaceutical classification system [G.L. Amidon, H.
Lennernas, V.P. Shah, J.R. Crison, Pharm. Res. (1995) 12:413-420]. Hence the limited oral
bioavailability is a major issue for oral formulation development.
If anhydrous solid forms of the compound of formula (I), as described in ,
are selected for clinical development, a physical instability in terms of hydrate formation during
pharmaceutical processing and/or storage of the drug product is possible. Anhydrous solid form
A of the compound of formula (I) as described in and herein, has further been
found to be only metastable and hence may convert into different solid forms. Hence there is a
need to find new solid forms which feature enhanced physicochemical properties and improved
ilability.
Further, the discovery of new solid forms of an API (polymorphs, solvates, salts, inclusion
complexes) enlarges the repertoire of als that a ation ist has available with
which to design a ceutical dosage form of a drug with a targeted release profile or other
desired characteristics. Therefore, there is a need to find more solid forms of the nd of
formula (I).
It has now been surprisingly found, that under certain conditions new solid forms,
particularly crystalline or amorphous forms, most particularly crystalline forms, of the compound
of formula (I) may be obtained, which are described hereinafter, which have ageous
utilities and properties. They exhibit ntially different and superior physical and
physicochemical properties which may be beneficial in various aspects relevant in API and drug
product development, e.g. for dissolution of API, stability and shelf live of API and drug product,
and/or facilitated routes of manufacturing or purification. The instant invention provides novel
solid forms of the compound of formula (I) with improved solubility, dissolution rate, oral
bioavailability as well as increased stability of the API.
In on, the instant invention provides novel inclusion complexes of compounds of
formula (I) with extrins. Such inclusion complexes r feature improved dissolution
rate and bioavailability.
The new solid forms as described herein are distinguishable by X-ray powder diffraction,
crystal structure is, vibrational oscopy, magnetic resonance and mass spectroscopy,
calorimetry, thermogravimmetry, dynamic vapour sorption as well as by microscopy.
Unless otherwise defined, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
belongs. Although methods and materials similar or equivalent to those bed herein can be
used in the practice or g of the invention, suitable methods and materials are described
below.
All publications, patent applications, patents, and other references ned herein are
incorporated by reference in their entirety.
The nomenclature used in this Application is based on IUPAC atic nomenclature,
unless indicated otherwise.
Any open valency appearing on a carbon, oxygen, sulfur or nitrogen atom in the structures
herein indicates the presence of a en, unless indicated otherwise.
The term “optional” or “optionally” denotes that a subsequently described event or
circumstance may but need not occur, and that the description includes instances where the event
or circumstance occurs and instances in which it does not.
The term “substituent” denotes an atom or a group of atoms replacing a hydrogen atom on
the parent molecule.
The term ituted” denotes that a ied group bears one or more tuents.
Where any group may carry multiple substituents and a variety of possible substituents is
provided, the substituents are independently selected and need not to be the same. The term
“unsubstituted” means that the ied group bears no substituents. The term nally
substituted” means that the specified group is unsubstituted or substituted by one or more
substituents, independently chosen from the group of possible substituents. When indicating the
number of substituents, the term “one or more” means from one substituent to the highest
possible number of substitution, i.e. replacement of one hydrogen up to replacement of all
hydrogens by substituents.
The term “halogen” s fluoro, chloro, bromo, or iodo. Particular halogen is fluoro.
The term “alkyl” s a lent linear or branched saturated hydrocarbon group of
1 to 12 carbon atoms. In particular embodiments, alkyl has 1 to 7 carbon atoms, and in more
particular embodiments 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, propyl,
isopropyl, n-butyl, iso-butyl, sec-butyl, or tert-butyl. Particular alkyl is methyl.
The term “alkoxy” denotes a group of the formula -O-R’, wherein R’ is an alkyl group.
Examples of alkoxy moieties include methoxy, ethoxy, isopropoxy, and tert-butoxy.
The term “haloalkyl” denotes an alkyl group wherein at least one of the hydrogen atoms of
the alkyl group has been replaced by same or different n atoms, particularly fluoro atoms.
es of haloalkyl include monofluoro-, difluoro- or oro-methyl, -ethyl or -propyl, for
example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, or
trifluoromethyl. The term “perhaloalkyl” denotes an alkyl group where all hydrogen atoms of the
alkyl group have been replaced by the same or different halogen atoms.
The term “hydroxyalkyl” denotes an alkyl group wherein at least one of the hydrogen
atoms of the alkyl group has been replaced by a hydroxy group. Examples of hydroxyalky
include hydroxymethyl, 2‑hydroxyethyl, oxypropyl, 3‑hydroxypropyl, 1-
(hydroxymethyl)methylpropyl, oxybutyl, 3‑hydroxybutyl, 4‑hydroxybutyl, 2,3‑
dihydroxypropyl, 2-hydroxyhydroxymethylethyl, 2,3‑dihydroxybutyl, 3,4‑dihydroxybutyl or
2‑(hydroxymethyl)-3‑hydroxypropyl.
The term “heterocycloalkyl” denotes a monovalent saturated or partly unsaturated monoor
bicyclic ring system of 3 to 9 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from
N, O and S, the remaining ring atoms being carbon. In particular embodiments, heterocycloalkyl
is a monovalent ted monocyclic ring system of 4 to 7 ring atoms, comprising 1, 2, or 3 ring
heteroatoms ed from N, O and S, the remaining ring atoms being . Examples for
monocyclic ted heterocycloalkyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl,
tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl,
lidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl,
thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, azepanyl, diazepanyl, homopiperazinyl, or
oxazepanyl. Examples for bicyclic ted heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl,
quinuclidinyl, 8-oxaaza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxaazabicyclo
[3.3.1]nonyl, or 3-thiaaza-bicyclo[3.3.1]nonyl. Examples for partly unsaturated
heterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or
dihydropyranyl. Particular heterocycloalkyl is (1,1-dioxo-1λ6-thiomorpholinyl).
The term “aromatic” denotes the tional idea of aromaticity as defined in the
literature, in particular in IUPAC - Compendium of al Terminology, 2nd, A. D.
ht & A. Wilkinson (Eds). Blackwell Scientific Publications, Oxford (1997).
The term “aryl” denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system
comprising 6 to 10 carbon ring atoms. Examples of aryl moieties include phenyl and naphthyl.
Particular aryl is phenyl.
The term “heteroaryl” s a monovalent aromatic heterocyclic mono- or bicyclic ring
system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the
remaining ring atoms being carbon. es of heteroaryl moieties include pyrrolyl, furanyl,
thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, zolyl, thiadiazolyl, tetrazolyl, pyridinyl,
pyrazinyl, pyrazolyl, zinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl,
benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl,
benzoxazolyl, soxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl,
benzothiadiazolyl, benzotriazolyl, l, inyl, isoquinolinyl, quinazolinyl, or
quinoxalinyl.
The term “active pharmaceutical ingredient” (or “API”) denotes the compound in a
pharmaceutical composition that has a particular ical activity.
The term “pharmaceutically acceptable” denotes an attribute of a material which is useful
in preparing a pharmaceutical ition that is generally safe, non-toxic, and neither
biologically nor otherwise undesirable and is acceptable for veterinary as well as human
pharmaceutical use.
The terms “pharmaceutically able excipient” and “therapeutically inert ent”
can be used interchangeably and denote any pharmaceutically acceptable ingredient in a
pharmaceutical composition having no therapeutic activity and being non-toxic to the subject
administered, such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers,
antioxidants, surfactants, carriers, diluents or lubricants used in formulating pharmaceutical
products.
The term “pharmaceutical composition” denotes a mixture or solution comprising a
therapeutically effective amount of an active pharmaceutical ient together with
pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need
thereof.
The term “solid form” or “form” is a general term to denote a crystal form and/or
amorphous form of a solid material.
The terms “crystal form” and “crystalline form” can be used interchangeably to denote
polymorphs and pseudo-polymorphs of a crystalline solid.
The terms “polymorph” and “modification” can be used mously to denote one
particular crystal structure in which a compound can crystallize. Different polymorphs have
different arrangements or conformations of the molecules in the crystal e but all share the
same elemental composition.
The term “polymorphism” s the y of a compound to form more than one
polymorph.
The term “enantiotropy” denotes the relationship between two or more polymorphs of the
same substance in which the rank order of thermodynamic stabilities of the polymorphs changes
reversibly at a defined temperature.
The term “monotropy” denotes the relationship between two or more crystal forms of the
same substance in which the rank order of thermodynamic stabilities of the polymorphs is
retained at all atures below the melting point. A table” form is a crystal form which
does not have the highest rank order of dynamic stability.
The terms “solvate” and “pseudo-polymorph” can be used synonymously to denote a
crystal having either stoichiometric or nonstoichiometric amounts of a solvent incorporated in
the crystal lattice. If the incorporated solvent is water, the solvate formed is a “hydrate”. When
the orated solvent is alcohol, the e formed is an “alcoholate”.
The term “salt” denotes a material which is composed of two components, an acid and a
base with a y defined stoichiometric ratio of the two salt formers. Salt crystals are formed
by ionic bonding interactions with complete transfer of hydrogen ions n acid and base.
The term “crystal shape” denotes the basic body element(s) (polyhedron(s)) of which a
single crystal is built up. The crystal shape is described by the Miller indices of the lattice planes
of the polyhedron(s).
The term “crystal habit” denotes the crystal morphology and hence the physical appearance
of a solid form. Variations of crystal habit are caused by different growth rates of lattice planes.
The following habits are distinguished [USP, General Chapter <776> (Optical Microscopy)]:
a) Equant crystals are equi-dimensional (like cubes or spheres);
b) Plates are flat, tabular crystals and have a similar breath and width; thicker than flakes;
c) Flakes are thin, flat ls that have a similar h and width; thinner than plates;
d) Blades (laths) are elongated, thin and blade-like crystals;
e) Needles are acicular, thin and highly elongated crystals having similar width and breadth;
f) Columns are elongated, prismatic crystals with greater width and thickness than needles.
The above crystal habits are illustrated in Figure 23.
The term “equivalent spherical diameter” (or ESD) of a non-spherical , e.g. an
irregularly-shaped particle, is the diameter of a sphere of equivalent volume.
The terms “d50 value” and “mass-median diameter” (or MMD) can be used
interchangeably and denote the e particle size by mass, i.e. the average equivalent
diameter of a particle, which is defined as the diameter where 50%(w) of the particles of the
ensemble have a larger equivalent spherical diameter, and the other 50%(w) have a smaller
equivalent spherical diameter.
The term “amorphous form” denotes a solid material which does not possess a
distinguishable crystal lattice and the molecular arrangement of molecules lacks a long-range
order. In particular, amorphous denotes a material that does not show a sharp Bragg diffraction
peak. Bragg’s law describes the diffraction of crystalline material with the equation “2d ·
eta) = n · lambda”, wherein “d” s dicular distance (in Angstroms) between
pairs of adjacent planes in a crystal (“d-spacing”), “theta” denotes the Bragg angle, “lambda”
denotes the wavelength and “n” is an integer. When Bragg’s law is fulfilled, the reflected beams
are in phase and ere constructively so that Bragg diffraction peaks are observed in the X-
ray diffraction pattern. At angles of incidence other than the Bragg angle, reflected beams are out
of phase and destructive erence or cancellation occurs. ous material does not satisfy
Bragg’s law and no sharp Bragg diffraction peaks are observed in the X-ray diffraction n.
The XRPD pattern of an ous material is further characterized by one or more amorphous
halos.
The term sion complex” denotes a iometric multicomponent complex. In
contrast to salts, no or only l proton transfer is expected in inclusion complexes. An
inclusion complex can be an ous form or a crystalline form. Particularly, an inclusion
complex is a crystalline form. Inclusion complex formers are solid at room temperature.
Particular inclusion complex former is cyclodextrin, most particularly γ-cyclodextrin (γ-CD).
Particularly the inclusion complex former is in crystalline state in the inclusion complex.
Particularly, an inclusion complex is a stoichiometric 1:1 or a 2:1 inclusion complex (ratio
between inclusion complex former and API). Most particularly, an inclusion complex is a
iometric 1:1 inclusion complex (ratio n inclusion complex former and
API).Inclusion complexes can form solvates, hydrates and can exist as ent polymorphic
forms.
The term “Form A” as used herein denotes the crystalline ous polymorphic form A
of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-
pyridinyl}-methanone.
The term “Form B” as used herein denotes the crystalline polymorphic form B of (1,1-
dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-
pyridinyl}-methanone monohydrate.
The term “Form C” as used herein denotes the crystalline anhydrous polymorphic form C
of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-
pyridinyl}-methanone.
The term “Form D” as used herein denotes the crystalline polymorphic form D of (1,1-
dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-
pyridinyl}-methanone trifluoroethanol mono-solvate.
The term “Form E” as used herein denotes the anhydrous crystalline polymorphic form E
of ioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-
pyridinyl}-methanone.
The term “Amorphous Form” as used herein denotes the amorphous form of (1,1-dioxo-
1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-
methanone.
The term “γ-CD inclusion complex” as used herein denotes the crystalline 1:1 inclusion
complex of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol
ylmethoxy]-pyridinyl}-methanone with γ-Cyclodextrin.
The term „XRPD” denotes the ical method of X-Ray Powder Diffraction. XRPD
patterns were recorded at ambient ions in transmission geometry with a STOE STADI P
diffractometer (Cu K alpha radiation source, primary monochromator, position sensitive detector,
angular range 3° to 42° 2Theta, approximately 60 minutes total measurement time). The
repeatability of the r values is in the range of 2Theta ±0.2°. The term “approximately”
given in combination with an r value denotes the repeatability which is in the range of
2Theta ±0.2°. The samples were prepared and analyzed without further processing (e.g. grinding
or sieving) of the substance. The relative XRPD peak intensity is ent upon many factors
such as structure factor, temperature factor, llinity, polarization factor, multiplicity, and
Lorentz factor. Relative intensities may vary considerably from one measurement to another due
to preferred orientation effects.
Humidity Controlled XRPD analyses were performed in reflection geometry with a
s D5000 Diffractometer (Cu radiation source, Ni K beta filter, llation detector,
angular range 3° to 42° 2Theta, approximately 180 minutes total measurement time per humidity
level). The diffractometer is equipped with an MRI (Materials Research ments) humidity
chamber. The humidity within the chamber is adjusted with an ANSYCO ty ller
(SYCOS H-HOT).
For single crystal structure analysis a single crystal sample was mounted in a nylon loop on
a goniometer and measured at ambient conditions. Alternatively, the crystal was cooled in a
nitrogen stream during measurement. Data were collected on a GEMINI R Ultra diffractometer
from Oxford Diffraction. Cu-radiation of 1.54 Å wavelength was used for data collection. Data
was processed with the Oxford Diffraction CRYSALIS software. The crystal ure was
solved and refined with standard crystallographic software. In this case the program ShelXTL
from Bruker AXS (Karlsruhe) was used.
The iation “FWHM” denotes the full width at half maximum, which is a width of a
peak (e.g. appearing in a spectrum, particularly in an XRPD pattern) at its half height.
The term “sharp Bragg diffraction peak” in connection with X-ray diffraction patterns
denotes a peak which is observed if Bragg’s law of diffraction is fulfilled. Generally, the FWHM
of a sharp Bragg diffraction peak is less than 0.5° 2-theta.
The term “amorphous halo” in connection with X-ray ction patterns denotes an
approximately bell-shaped diffraction maximum in the X-ray powder diffraction pattern of an
amorphous material. The FWHM of an amorphous halo is on ple larger than the FWHM of
the peak of crystalline material.
The terms “FTIR” and “IR” denote the analytical method of infrared spectroscopy. The IR-
spectra of the samples are recorded as film of a Nujol sion consisting of . 5 mg of
sample and approx. 5 mg of Nujol (mineral oil) between two sodium chloride plates (cross
section 13 mm) in transmittance with a FTIR-spectrometer. The spectra were recorded in
spectral range between 4000 cm-1 and 600 cm-1, resolution 2 cm-1, and 300 d scans on a
Magna 860 (thermo/Nicolet) equipped with a DTGS detector.
The term “Raman” denotes the analytical method of Raman spectroscopy. For recording
Raman spectra, the samples were spread on a glass slide. Raman spectra were recorded in the
range of 150-3800 cm-1 with an ARAMIS (HoribaJobinYvon) Raman microscope ed with
a Peltier cooled CCD detector, at excitation of 633 nm, a 1200 l/mm grating, a x50 objective and
with 3 res of 3s, or 7s for weak Raman scatterers.
The term “DSC” denotes the analytical method of ential Scanning Calorimetry. DSC
thermograms were recorded using a Mettler-Toledo™ differential ng calorimeter DSC820,
DSC821 or DSC1 with a FRS05 sensor. System suitability tests were performed with Indium as
reference substance and calibrations were carried out using Indium, Benzoic acid, Biphenyl and
Zinc as reference substances.
For the measurements, approximately 2 - 6 mg of sample were placed in aluminum pans,
accurately weighed and hermetically closed with perforation lids. Prior to measurement, the lids
were automatically pierced resulting in approx. 1.5 mm pin holes. The s were then heated
under a flow of nitrogen of about 100 mL/min using heating rates of usually 10 K/min.
For the measurements of amorphous forms, approximately 2 - 6 mg of sample were placed in
aluminum pans, accurately weighed and hermetically closed. The samples were then heated
under a flow of en of about 100 mL/min using heating rates of 10 K/min.
The term “onset” denotes the intersection point of the baseline before transition and the
interflection tangent.
The term “glass transition temp” (Tg) denotes the temperature above which a glassy
amorphous solid becomes rubbery.
The term “TGA” denotes the analytical method of Thermo etric Analysis. TGA
analysis was performed on a Mettler-Toledo™ thermogravimetric analyzer (TGA850 or
TGA851). System suitability tests were med with Hydranal as reference substance and
ations using Aluminum and Indium as reference substances.
For the gravimetric analyses, approx. 5 - 10 mg of sample were placed in aluminum pans,
accurately weighed and ically closed with perforation lids. Prior to measurement, the lids
were automatically pierced resulting in approx. 1.5 mm pin holes. The samples were then heated
under a flow of nitrogen of about 50 mL/min using a heating rate of 5 K/min.
The term “micronization” denotes a process whereby the particle size of a solid material is
shed to a d50 value of less than 10µm by the aid of a suitable method, such as milling,
bashing or grinding.
The term “polishing filtration” denotes a filtration process wherein a solution is filtrated
using a 0.2 µm filter, particularly a Pall N66 Posidyne® 0.2 µm filter dge, to remove fine
particles.
The term “distillative solvent exchange” denotes a thermal distillation under reduced or
normal pressure wherein one liquid (solvent or antisolvent) is replaced by another liquid (solvent
or antisolvent), usually under constant reactor liquid level.
The term “solvent” denotes any kind of liquid in which the product is at least partially
soluble ility of product > 1g/l).
The term “antisolvent” denotes any kind of liquid in which the t is insoluble or at
maximum gly soluble (solubility of product < 0.01mol/l).
The term “anti-solvent crystallization” denotes a s wherein supersaturation and as a
result thereof crystallisation is achieved by addition of an antisolvent to the product solution.
The term “ambient conditions” denotes conditions as experienced in a standard laboratory,
e.g. atmospheric pressure, air, ambient ature between 18 °C and 28 °C, humidity between
30 %rH and 80 %rH.
The term scopicity” describes the ability of a solid material to adsorb moisture. The
hygroscopicity of a given API is characterized [European Pharmacopoeia - 6th Edition (2008),
Chapter 5.11) by the increase in mass when the relative humidity is raised from 0 %rH to 90
%rH:
○ non-hygroscopic: weight increase ∆m < 0.2%;
○ ly hygroscopic: weight increase 0.2% ≤ ∆m < 2.0%;
○ hygroscopic: weight increase 2.0% ≤ ∆m < 15.0%;
○ very hygroscopic: weight increase ∆m ≥ 15.0%;
○ deliquescent: sufficient water is adsorbed to form a liquid.
The IUPAC lamda convention (W.H. Powell, Pure & Appl. Chem. (1984) 56(6): 769-778)
provides a general method for indicating nonstandard valence states of atoms in a
molecule. The bonding number “n” of a heteroatom is the sum of the total number of e
bonds to adjacent atoms, if any, and the number of attached hydrogen atoms. The bonding
number of a heteroatom is rd when it has the value given in the following table:
n=4: C, Si, Ge, Sn, Pb;
n=3: B, N, P, As, Sb, Bi
n=2: O, S, Se, Te, Po;
n=1; F, Cl, Br, I, At.
A non-standard bonding number of a (neutral) heteroatom is indicated by the symbol “λn”, where
“n” is the bonding number. If the locant, the number indicating the position within the molecule,
for a heteroatom with a ndard bonding number is used, the λn symbol is cited immediately
after this .
The terms (1,1-dioxo-1λ6-thiomorpholinyl)-, (1,1-dioxo-1λ6-thiomorpholinyl)-, (1,1-
dioxo-1λ6-thiomorpholinyl)-, and (1,1-dioxo-thiomorpholinyl)- are used herein
interchangeably to denote a thiomorpholinyl-radical wherein the sulfur ringatom is substituted
with two oxo groups of the structure as follows:
N S
Detailed description of the invention
In one aspect, the present invention es a novel solid form of a compound of formula
N S
N O
F (I)
wherein the solid form is crystalline 1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluorophenyl
)methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous
polymorphic form C, characterized by an XRPD diffraction n comprising XRPD peaks
at angles of diffraction 2Theta (CuKα) of 11.7° ± 0.2°, 17.4° ± 0.2°, 23.4° ± 0.2°.
(1,1-Dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol
ylmethoxy]-pyridinyl}-methanone [CAS No. 11596005] refers to the compound of
formula (I) and vice versa.
The present invention is as defined in the claims and relates to the solid form C of the
compound of formula (I). However, the description which s also refers to additional solid
crystalline and amorphous forms of the compound of formula (I). This description is retained for
technical information.
In a particular embodiment of the ion, the solid form C of a compound of formula (I)
as described above is present in the specified solid form in a purity of at least 90%(w/w),
particularly at least 95%(w/w), most particularly at least 99%(w/w).
(1,1-Dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol
ylmethoxy]-pyridinyl}-methanone in anhydrous polymorphic form A (Form A) has been
described in WO 71476.
Form A has been found to be a metastable polymorph with a melting temperature of
. 145 °C (extrapol. peak DSC). Due to its able character Form A is not optimally
suited for drug product development.
Form A is characterized by XRPD peaks at angles of diffraction 2Theta of 3.3°, 10.1°,
14.2°, 14.4°, 15.7°, 16.1°, 17.2°, 17.3°, 19.5°, 19.8°, 20.2°, 20.8°, 22.5°, 24.8°, 25.0°, 25.9°,
27.7°; particularly by XRPD peaks observed at an angle of diffraction 2Theta of 14.4°, 20.2°,
22.5°, 25.9°.
Form A is characterized by the XRPD diffraction pattern of figure 1.
Form A is characterized by an XRPD diffraction pattern comprising XRPD peaks at peak
positions as denoted in Table 2.
Form A is characterized by the FTIR um of figure 8.
Form A is characterized by the Raman spectrum of figure 14.
Form A is characterized by a melting point with onset temperature (DSC) in the range of
about 141 °C to 145 °C.
It has been found that (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)
methyl-isoxazolylmethoxy]-pyridinyl}-methanone can be isolated, depending upon the
method of preparation, in other different crystalline and amorphous modifications, which are
distinguishable by their X-ray powder ction patterns, vibrational spectra and their melting
behaviour and which exhibit surprising but relevant advantages beneficial for API and drug
product development and administration as compared to previously described Form A.
s the previously bed Form A of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone, two further
polymorphic ous forms (Form C and Form E), one monohydrate form (Form B), a
trifluoroethanol form (Form D), as well as an amorphous form were ered and
characterised.
Form B of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol-
4-ylmethoxy]-pyridinyl}-methanone is a hygroscopic mono-hydrate that transforms into Form
A upon heating to >100 °C. Stability of Form B is substantially increased as compared to Form
A in the presence of humidity, e.g. at ambient conditions.
Temperature Controlled XRPD analyses of Form B show a phase transition to Form A at
elevated temperature. In the temperature range 105-135°C only Form A is present. In the
temperature range of 65-95°C an intermediate state is observed that is characterized by
significant s in peak positions.
Also described herein is crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-
phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone monohydrate in polymorphic
form B (Form B).
In a particular embodiment, Form B is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of approximately 13.3°, 20.6°, 22.5°.
In a particular embodiment, Form B is characterized by an XRPD diffraction pattern
sing XRPD peaks at angles of diffraction 2Theta of approximately 10.9°, 13.0°, 13.3°,
14.1°, 14.8°, 16.5°, 17.0°, 18.9°, 20.6°, 21.0°, 22.5°, 23.4°, 24.8°, 26.9°.
In a ular embodiment, Form B is characterized by the XRPD diffraction pattern of
figure 2.
In a ular embodiment, Form B is terized by an XRPD diffraction pattern
comprising XRPD peaks at peak positions as denoted in Table 3.
In a ular embodiment, Form B is terized by the FTIR spectrum of figure 9.
In a particular embodiment, Form B is characterized by the Raman spectrum of figure 15.
In a particular embodiment, Form B is characterized by a broad endothermic signal from
90 °C to 110 °C accompanied by weight loss (measured by TGA).
Form C of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol-
4-ylmethoxy]-pyridinyl}-methanone has been found to be more stable than Form A. In fact,
Form C has been found to be the most stable polymorph overall. Form C is in addition less
hygroscopic than Form A and has a melting temperature of approx. 151 °C pol. peak DSC).
The solubility in simulated gastric fluid (SGF) of Form C is considerably improved as compared
to Form B. In the presence of water, Form C transforms into Form B in ded state, whereas
storage at 100 %rH at ambient temperature for a prolonged period of time, e.g. for 30 days does
not induce this phase change.
Temperature Controlled XRPD analyses of polymorphs Form A and Form C do not show
solid form changes at elevated temperature.
One particular embodiment of the ion relates to crystalline (1,1-dioxo-1λ6-
thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-
methanone in anhydrous polymorphic form C (Form C) as described herein.
Form C is characterized by an XRPD diffraction pattern comprising XRPD peaks at angles
of diffraction 2Theta of approximately 11.7°, 17.4°, 23.4°.
In a ular embodiment of the invention, Form C is characterized by an XRPD
diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta of approximately
.5°, 11.7°, 14.2°, 16.3°, 16.7°, 17.4°, 17.9°, 19.3°, 23.4°, 24.7°, 25.1°, 25.9°.
In a particular embodiment of the invention, Form C is characterized by the XRPD
diffraction pattern of figure 3.
In a particular embodiment of the invention, Form C is characterized by an XRPD
diffraction pattern sing XRPD peaks at peak positions as d in Table 4.
In a particular embodiment of the invention, Form C is characterized by the FTIR spectrum
of figure 10.
In a ular embodiment of the invention, Form C is terized by the Raman
spectrum of figure 16.
In a particular embodiment of the invention, Form C is characterized by a melting point
with onset temperature (DSC) in the range of about 146 °C to 150 °C.
Form D of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol-
4-ylmethoxy]-pyridinyl}-methanone is a trifluoroethanol mono-solvate that can be generated
by crystallization from trifluoroethanol/methanol mixtures. Form D is offers the t over
Form A, that it is readily obtainable in case trifluoroethanol is employed in the manufacturing
process.
Also described herein is crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluorophenyl
)methyl-isoxazolylmethoxy]-pyridinyl}-methanone trifluoroethanol lvate
in polymorphic form D (Form D). Form D has a melting temperature of approx. 97.9°C
(extrapol. peak DSC)
In a particular embodiment, Form D is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of approximately 6.1°, 16.8°, 22.6°.
In a ular embodiment, Form D is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of approximately 6.1°, 11.0°, 16.8°,
22.6°.
In a particular embodiment, Form D is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of approximately 6.1°, 8.1°, 11.0°, 13.5°,
.4°, 16.8°, 18.4°, 19.2°, 19.5°, 21.1°, 21.4°, 22.6°, 24.7°, 28.1°.
In a particular embodiment, Form D is terized by the XRPD diffraction pattern of
figure 4.
In a particular embodiment, Form D is characterized by an XRPD diffraction pattern
comprising XRPD peaks at peak positions as denoted in Table 5.
In a particular embodiment, Form D is terized by the FTIR um of figure 11.
In a particular embodiment, Form D is characterized by a melting point with onset
ature (DSC) in the range of about 96°C to 100 °C.
Form E of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazol-
4-ylmethoxy]-pyridinyl}-methanone is an anhydrate which exhibits only limited stability at
ambient conditions. Form E is obtained by dehydration of Form B through storage at <5 %rH. A
rapid reconversion of Form E into Form B is observed upon exposure to >5 %rH.
Similarly, also upon drying monohydrate form B by means of Humidity Controlled XRPD
analysis Form E is observed at 0%rH.
Also described herein is crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluorophenyl
)methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous polymorphic
form E (Form E).
In a particular embodiment, Form E is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of imately 16.5°, 20.8°.
In a particular embodiment, Form E is characterized by an XRPD diffraction n
comprising XRPD peaks at angles of diffraction 2Theta of approximately 13.1°, 16.5°, 20.8°.
In a particular ment, Form E is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of ction 2Theta of approximately 5.5°, 13.1°, 13.3°,
14.2°, 16.5°, 19.1°, 20.8°, 22.3°, 23.9°, 25.1°, 25.5°, 26.4°, 29.0°.
In a particular embodiment, Form E is characterized by an XRPD diffraction pattern
comprising XRPD peaks at peak positions as denoted in Table 6.
In a particular embodiment, Form E is characterized by the XRPD diffraction pattern of
figure 5.
In a particular embodiment, Form E is characterized by the Raman spectrum of figure 17.
The glass transition ature of the amorphous Form of (1,1-dioxo-1λ6-thiomorpholin-
4-yl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone is
approx. 66 °C (midpoint of second g). Amorphous material is slightly hygroscopic, but no
phase transformation has been observed upon storage at 100 %rH at ambient temperature.
Also described herein is amorphous (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-
phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone (Amorphous Form).
In a particular ment, Amorphous Form is characterized by at least one amorphous
halo and a lack of a sharp Bragg diffraction peak in the XRPD diffraction pattern.
In a particular embodiment, Amorphous Form is characterized by the XRPD ction
pattern of figure 6.
In a particular embodiment, Amorphous Form is characterized by the FTIR spectrum of
figure 12.
In a particular embodiment, Amorphous Form characterized by the Raman spectrum of
figure 18.
In a particular embodiment, Amorphous Form is characterized by a glass transition
temperature Tg of 60°C to 70 °C, particularly 65°C to 67°C, most particularly 66°C.
In addition, a 1:1 inclusion complex of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone with γ-Cyclodextrin
(γ-CD inclusion x) with beneficial ties has been found and is bed . The
γ-CD inclusion complex is highly crystalline (as confirmed by XRPD). The dried γ-CD inclusion
complex has been found to se a residual water content of approx. 7.3% (as confirmed by
TGA). It was found, that dried γ-CD inclusion complex and wet powder sample show different
XRPD patterns. The crystal structure of the γ-CD complex seems to be dependent on the water
content of the sample. Water seems to stabilize the crystal structure of the bed inclusion
x and a substantial loss of water could lead to changes of the crystal structure. γ-CD
inclusion complex comprising residual water has been found to have an improved solubility in
water as compared to dried γ-CD inclusion complexes [T. Toropainen et al., Pharm. Res. (2007)
24:1058-1066]. The molar ratio between API and γ-CD in the γ-CD inclusion complex has been
found to be 1:1 (as confirmed by UPLC). A complex binding constant of 510.4 M-1 was
calculated for the inclusion complex of compounds of formula (I) and of γ-CD, as described
herein. This binding constant and in vitro dissolution profiles indicate an increased dissolution
rate and thus enhanced bioavailability as compared to other solid forms es 21 & 22).
One particular embodiment s to a 1:1 inclusion x of (1,1-dioxo-1λ6-
thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-
methanone with γ-Cyclodextrin (γ-CD inclusion complex) as described herein.
One particular embodiment relates to a 1:1 inclusion complex of (1,1-dioxo-1λ6-
thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-
methanone with γ-Cyclodextrin (γ-CD inclusion complex) as described herein, comprising a
residual water t of 1% to 20%(w/w), particularly 5% to 15%(w/w), most particularly 8%
to 12%(w/w).
In a particular embodiment, Form E is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of approximately 7.4°, 14.9°, 16.7°,
21.8°.
In a particular embodiment, Form E is characterized by an XRPD diffraction pattern
comprising XRPD peaks at angles of diffraction 2Theta of approximately 7.4°, 12.1°, 14.9°,
16.7°, 21.8°.
In a particular embodiment, Form E is characterized by an XRPD ction n
comprising XRPD peaks at angles of diffraction 2Theta of approximately 3.8°, 5.2°, 7.4°, 9.2°,
.6°, 11.5°, 11.8°, 12.1°, 14.2°, 14.9°, 15.8°, 16.7°, 19.2°, 20.3°, 21.2°, 21.8°, 22.5°, 23.7°,
26.8°.
In a particular embodiment, γ-CD inclusion x is characterized by the XRPD
diffraction pattern of figure 7.
In a particular ment, γ-CD inclusion complex is characterized by an XRPD
diffraction pattern comprising XRPD peaks at peak positions as denoted in Table 7.
In a particular embodiment, γ-CD inclusion complex is characterized by the FTIR
spectrum of figure 13.
In a particular embodiment, γ-CD inclusion complex is characterized by the Raman
spectrum of figure 19.
Table 1 lists the relevant crystal structure data of Form A, Form B, Form C and Form D of
(1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-
pyridinyl}-methanone. The crystal structures of Form A, Form B, Form C and Form D were
refined. Form E crystallizes only at dry conditions and ates at relative humidity >5%,
single crystalline samples are not available.
The lattice constants, unit cell volume and calculated density are based on ambient
temperature data. For this purpose the lattice constants obtained from single l structure
analysis were refined with the mental ambient ions XRPD reference patterns using
the software TOPAS 4.0, Bruker AXS.
Table 1: Single Crystal Structural Data of Forms A, B, C and D
Crystal form Form A Form B Form C Form D
Solid form trifluoroethanol
anhydrate monohydrate ate
ption monosolvate
Measuring
295 K 130 K 100 K 293 K
Temperature
Crystal system Monoclinic Monoclinic Triclinic Monoclinic
Space group P2(1)/c P2(1)/n P1 P2(1)/c
Unit cell dimensions
26.1638 Å 7.5969 Å 7.653 Å 14.6152 Å
b= 6.3113 Å 32.0909 Å 7.8637 Å 9 Å
c= 12.4695 Å 8.9480 Å 17.394 Å 10.6567 Å
α= 90° 90° 81.078° 90°
β= 90.836° 110.454° 78.195° 98.934°
γ= 90° 90° 87.98° 90°
Cell volume 2058.84 Å3 2043.91 Å3 1012.2 Å3 2555.1 Å3
API molecules in unit
4 4 2 4
cell
Calculated density 1.437 g/cm3 1.506 g/cm3 1.462 g/cm3 1.418 g/cm3
* ambient temperature data
Tables 2, 3 and 4: XRPD peak positions and relative intensities of major XRPD peaks of
Forms A, B and C.
Table 2 Table 3 Table 4
Form A Form B Form C
2Theta/° rel. int./% * 2Theta/° rel. int./% * 2Theta/° rel. int./% *
3.3 16.2 10.9 28.8 5.2 8.2
.1 20.2 13.0 28.7 10.5 14.4
14.2 89.6 13.3 70.4 11.7 15.5
14.4 100 14.1 27.3 14.2 8.1
.7 60.6 14.8 49.9 16.3 26.2
16.1 28.6 16.5 45.7 16.7 32.8
17.2 39.9 17.0 29.9 17.4 34.9
17.3 43.5 18.9 49.6 17.9 8.9
19.5 47.3 20.6 98.6 19.3 25.6
19.8 41.7 21.0 52.8 23.4 100
.2 82.8 22.5 100 24.7 15.3
.8 25.7 23.4 43.1 25.1 14.7
22.5 94.1 24.8 32 25.9 31.3
24.8 24 26.9 33.1
.0 28.1
.9 93.4
27.7 25.5
* ve intensities may vary considerably from one measurement to another.
Tables 5, 6 and 7: XRPD peak positions and relative intensities of major XRPD peaks of
Forms D, E and γ-CD inclusion complex.
Table 5 Table 6 Table 7
Form D Form E γ-CD inclusion complex
2Theta/° rel. int./% * 2Theta/° rel. int./% * 2Theta/° rel. int./% *
6.1 18.1 5.5 9.7 3.8 14.8
8.1 9.1 13.1 23.4 5.2 11.6
11.0 16.9 13.3 19.2 7.4 100
13.5 16.2 14.2 18.7 9.2 12.1
.4 20.7 16.5 81 10.6 13.8
16.8 100 19.1 47.7 11.5 32.9
18.4 30.7 20.8 100 11.8 21.3
19.2 43.7 22.3 34.4 12.1 38.6
19.5 25.1 23.9 66.8 14.2 49.7
21.1 27.2 25.1 20.4 14.9 61.1
21.4 39.7 25.5 19.8 15.8 47.1
22.6 78.2 26.4 45.1 16.7 60
24.7 22.8 29.0 31 19.2 27.2
28.1 14.6 20.3 26.9
21.2 28.6
21.8 62.3
22.5 32.9
23.7 31.3
26.8 20.7
* Relative intensities may vary considerably from one measurement to another.
The invention r relates to a distillative solvent exchange process for the ation
of solid form C of a compound of formula (I) as defined above comprising:
a) dissolution of the educt solid form in a solvent;
b) distillation of the solvent while keeping the reactor liquid level constant by
replacing the distillate by an antisolvent;
c) al separation of the desired solid form from the suspension.
The solvent employed in step a) is selected from THF, DMF or e or a mixture
thereof, particularly selected from THF.
The lvent employed in step b) is selected from ethanol, iso-propanol, or n-heptane or
a e thereof, particularly selected from ethanol.
Step b) is performed at increased temperature, particularly at 50-80°C.
According to the invention, the desired solid form obtained by such distillative solvent
ge in step c) is crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)
methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous polymorphic form C
(Form C) as defined above.
In a particular embodiment, the educt solid form in step a) is selected from Form A or
Form B, most particularly from Form B.
In a particular embodiment, step b) is performed at reduced pressure, particularly at 100-
300mbar.
In a particular embodiment, step b) is optionally preceded or accompanied by seeding with
the d solid form as a powder or suspension, most particularly seeding with 1-10%(w/w) (in
respect of final yield) of the desired solid form as a powder or sion.
In a particular embodiment, the physical tion in step c) is performed via filtration.
The ion further relates to a high-shear process for the preparation of solid form C of
a compound of formula (I) as d above comprising:
d) injection of a solution of the educt solid form in a solvent into a high-shear mixer
comprising an antisolvent;
e) agitation of the stator system of the high-shear mixer;
f) physical separation of the desired solid form from the suspension.
The solvent employed in step d) is selected from THF, DMF or acetone or a mixture
thereof, particularly selected from THF.
The antisolvent employed in step d) is selected from ethanol, iso-propanol, or ane or
a mixture thereof, particularly selected from n-heptane.
The antisolvent of step d) comprises 5-10%(w/w) (in respect of final yield) of seeding
particles of the desired solid form.
Steps d) and e) are performed at sed temperature, particularly at -20°C to 0°C, most
particularly at -5°C.
ing to the invention, the desired solid form obtained by this high-shear process in
step f) is crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methylisoxazolylmethoxy
dinyl}-methanone in anhydrous polymorphic form C (Form C) as
defined above.
In a particular embodiment, the educt solid form in step d) is selected from Form A or
Form B, particularly selected from Form B.
In a particular embodiment, the solution of educt solid form in step d) is injected at a
nt flow rate of in.
In a particular embodiment, the antisolvent is circulated across the high-shear mixer in
steps d) and e) at a constant velocity, particularly at a constant velocity of 20 l/h.
In a particular ment, the rotor-stator system in step e) is rotated at a rotation rate of
15000 RPM to 24000 RPM.
In a particular embodiment, the physical separation in step f) is performed via filtration.
Another embodiment provides pharmaceutical itions or medicaments sing
solid form C of a compound of formula (I) as described herein and a pharmaceutically acceptable
excipient, as well as s of using the compounds of the invention to e such
compositions and medicaments.
Compositions are formulated, dosed, and administered in a fashion consistent with good
medical practice. Factors for consideration in this context include the particular disorder being
treated, the particular mammal being treated, the clinical condition of the individual patient, the
cause of the disorder, the site of delivery of the agent, the method of administration, the
scheduling of administration, and other factors known to medical practitioners.
The solid forms of compounds of formula (I) as described herein may be administered by
any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal,
transdermal, parenteral, subcutaneous, intraperitoneal, ulmonary, intradermal, intrathecal
and epidural and intranasal, and, if desired for local treatment, intralesional administration.
Parenteral infusions include uscular, enous, intraarterial, intraperitoneal, or
subcutaneous stration.
The solid forms of compounds of formula (I) as described herein may be administered in
any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions,
sions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may
comprise components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH
modifiers, preservatives, solubilizers, stabilizers, g agents, emulsifiers, sweeteners,
colorants, flavorants, salts for g the osmotic pressure, buffers, g agents,
antioxidants, and further active agents. They can also comprise still other therapeutically
valuable substances.
A typical formulation is ed by mixing a solid form of compounds of formula (I) as
described herein and a pharmaceutically able excipient. Suitable excipients are well
known to those skilled in the art and are described in detail in, e.g., Ansel H.C. et al., Ansel’s
Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) cott, Williams &
Wilkins, Philadelphia; Gennaro A.R. et al., Remington: The e and Practice of Pharmacy
(2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C, Handbook of
Pharmaceutical Excipients (2005) Pharmaceutical Press, o. The formulations may also
include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating ,
fiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing
aids, nts, sweeteners, perfuming agents, flavoring agents, diluents and other known
additives to provide an elegant presentation of the drug (i.e., a compound of the present
invention or pharmaceutical composition f) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament).
The dosage at which solid forms of compounds of formula (I) as described herein can be
administered can vary within wide limits and will, of course, be fitted to the individual
requirements in each particular case. In general, in the case of oral administration a daily dosage
of about 0.1 to 1000 mg per person of a solid form of compounds of formula (I) as described
herein should be appropriate, although the above upper limit can also be exceeded when
necessary. A particular embodiment of the invention s to a daily dosage of 0.1 to 1000 mg
(p.o.), particularly of 10 to 500 mg (p.o.), most particularly of 75 to350 mg (p.o.).
An e of a suitable oral dosage form is a tablet comprising about 100 mg to 500 mg
of a solid form of compounds of formula (I) as described herein compounded with about 90 to 30
mg anhydrous lactose, about 5 to 40 mg sodium croscarmellose, about 5 to 30 mg
polyvinylpyrrolidone (PVP) K30, and about 1 to 10 mg magnesium stearate. The powdered
ingredients are first mixed together and then mixed with a solution of the PVP. The resulting
composition can be dried, granulated, mixed with the magnesium stearate and ssed to
tablet form using conventional equipment.
An example of an aerosol formulation can be prepared by dissolving a solid form of
compounds of a (I) as described herein, for example 10 to 100 mg, in a suitable buffer
solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such as sodium chloride, if
desired. The solution may be filtered, e.g., using a 0.2 µm filter, to remove impurities and
contaminants.
The solid forms of compounds of a (I) as described herein, possess valuable
pharmacological properties and have been found to be ligands for GABA A α5 receptors. The
solid forms of compounds of formula (I) bed herein can therefore be used, either alone or
in combination with other drugs, for the treatment or prevention of diseases which are modulated
by ligands for GABA A ors containing the α5 subunit. These diseases include, but are not
limited to acute and/or chronic neurological ers, cognitive disorders, Alzheimer’s disease,
memory deficits, schizophrenia, positive, ve and/or ive symptoms associated with
schizophrenia, bipolar disorders, autism, Down me, ibromatosis type I, sleep
disorders, disorders of circadian rhythms, amyotrophic lateral sis (ALS), dementia caused
by AIDS, psychotic disorders, substance-induced psychotic er, anxiety disorders,
generalized y disorder, panic disorder, delusional disorder, obsessive/compulsive disorders,
acute stress disorder, drug addictions, movement disorders, Parkinson’s disease, restless leg
syndrome, cognition deficiency disorders, multi-infarct dementia, mood disorders, sion,
sychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, neuropathic pain,
stroke, Multiple Sclerosis (MS), acute Meningitis, Fetal Alcohol Syndrome, attentional disorders,
CNS conditions occurring after stroke, and need for cognition enhancement.
The ion therefore also relates to pharmaceutical compositions comprising solid form
C of a compound of formula (I) as described herein and a pharmaceutically acceptable excipient.
The invention likewise embraces solid form C of a nd of formula (I) as described
herein for use as therapeutically active substances.
The invention likewise embraces solid form C of a compound of formula (I) as described
herein for use as therapeutically active substances for the treatment or prevention of diseases
which are related to the GABA A α5 receptor.
The invention likewise embraces solid form C of a compound of formula (I) as described
herein for use as therapeutically active nces for the treatment or prevention of acute and/or
c neurological disorders, ive disorders, Alzheimer’s disease, memory deficits,
schizophrenia, positive, negative and/or cognitive symptoms ated with schizophrenia,
bipolar disorders, autism, Down syndrome, neurofibromatosis type I, sleep disorders, disorders
of circadian rhythms, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, psychotic
disorders, substance-induced psychotic disorder, anxiety disorders, generalized anxiety disorder,
panic disorder, delusional disorder, obsessive/compulsive disorders, acute stress disorder, drug
addictions, movement ers, son’s disease, restless leg syndrome, cognition deficiency
disorders, multi-infarct dementia, mood disorders, depression, neuropsychiatric conditions,
psychosis, ion-deficit/hyperactivity disorder, neuropathic pain, stroke, Multiple Sclerosis
(MS), acute Meningitis, Fetal Alcohol Syndrome, and attentional disorders, for stroke recovery
therapy, or for use as cognitive enhancers.
Also described herein is a method for the treatment or tion of diseases which are
related to the GABA A α5 receptor, which method comprises administering solid forms of
compounds of formula (I) as described herein to a human being or animal.
Also described herein is a method for the treatment or prevention of acute and/or chronic
ogical ers, cognitive disorders, Alzheimer’s disease, memory deficits, schizophrenia,
positive, negative and/or cognitive symptoms associated with schizophrenia, bipolar disorders,
, Down syndrome, neurofibromatosis type I, sleep disorders, disorders of circadian
rhythms, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, psychotic ers,
substance-induced psychotic disorder, anxiety disorders, generalized y disorder, panic
disorder, delusional disorder, obsessive/compulsive disorders, acute stress disorder, drug
addictions, movement disorders, son’s disease, restless leg syndrome, cognition deficiency
disorders, infarct dementia, mood disorders, depression, neuropsychiatric conditions,
sis, attention-deficit/hyperactivity disorder, neuropathic pain, , Multiple Sclerosis
(MS), acute Meningitis, Fetal Alcohol Syndrome, and ional disorders, for stroke recovery
therapy, or for cognition enhancement, which method comprises administering solid forms of
compounds of formula (I), particularly compounds of formula (I),as described herein to a human
being or animal.
Also described herein is the use of solid forms of compounds of formula (I) as described
herein for the treatment or prevention of diseases which are related to the GABA A α5 or.
Also described herein is the use of solid forms of compounds of formula (I) as described
herein for the treatment or prevention of acute and/or chronic neurological disorders, cognitive
disorders, Alzheimer’s disease, memory deficits, phrenia, positive, negative and/or
ive symptoms associated with schizophrenia, bipolar disorders, autism, Down syndrome,
neurofibromatosis type I, sleep disorders, disorders of circadian rhythms, amyotrophic lateral
sclerosis (ALS), dementia caused by AIDS, psychotic disorders, substance-induced psychotic
disorder, anxiety disorders, generalized anxiety er, panic disorder, delusional disorder,
obsessive/compulsive disorders, acute stress disorder, drug addictions, movement disorders,
son’s disease, restless leg syndrome, cognition deficiency disorders, multi-infarct
dementia, mood disorders, depression, neuropsychiatric ions, psychosis, attentiondeficit
/hyperactivity disorder, neuropathic pain, stroke, Multiple Sclerosis (MS), acute
Meningitis, Fetal Alcohol Syndrome, and ional disorders or for cognition enhancement.
The ion also relates to the use of solid form C of a compound of formula (I) as
described herein for the preparation of medicaments for the ent or tion of diseases
which are related to the GABA A α5 receptor, particularly for the treatment or prevention of
acute and/or chronic ogical disorders, cognitive ers, Alzheimer’s disease, memory
deficits, schizophrenia, positive, negative and/or cognitive symptoms associated with
schizophrenia, bipolar ers, autism, Down syndrome, neurofibromatosis type I, sleep
disorders, ers of circadian rhythms, amyotrophic lateral sclerosis (ALS), dementia caused
by AIDS, psychotic disorders, substance-induced psychotic disorder, y disorders,
generalized anxiety disorder, panic disorder, delusional disorder, obsessive/compulsive disorders,
acute stress disorder, drug addictions, movement disorders, Parkinson’s disease, restless leg
syndrome, cognition ency disorders, infarct dementia, mood disorders, depression,
neuropsychiatric conditions, psychosis, ion-deficit/hyperactivity disorder, neuropathic pain,
stroke, Multiple Sclerosis (MS), acute Meningitis, Fetal Alcohol Syndrome, and attentional
disorders, for stroke recovery therapy, or for the preparation of ive enhancers. Such
medicaments comprise a compound as described above.
Also described herein is the use of solid forms of compounds of formula (I) as described
herein for the treatment, prevention and/or delay of progression of CNS conditions caused by
evelopmental defects which result in ive GABAergic inhibition in the cortex and
hippocampus, wherein the CNS condition is ed from cognitive deficits in Down Syndrome,
in autism, in neurofibromatosis type I, or after stroke.
The treatment or prevention of cognitive disorders, Alzheimer’s disease, schizophrenia,
positive, negative and/or cognitive symptoms associated with schizophrenia, Down syndrome,
and neurofibromatosis type I, are particular embodiments of present invention.
A particular embodiment of the ion embraces the treatment or prevention of
Alzheimer’s disease.
A particular embodiment of the invention embraces the treatment or prevention of Down
syndrome.
A particular embodiment of the invention embraces the treatment or prevention of
neurofibromatosis type I.
A particular embodiment of the invention embraces the recovery after stroke.
Description of the drawings
Figure 1: XRPD pattern of Form A.
Figure 2: XRPD pattern of Form B.
Figure 3: XRPD pattern of Form C.
Figure 4: XRPD pattern of Form D.
Figure 5: XRPD pattern of Form E, analyzed at 0%rH or after drying at 70°C.
Figure 6: XRPD pattern of amorphous Form.
Figure 7: XRPD pattern γ-CD inclusion complex.
Figure 8: FT-IR spectrum of Form A.
Figure 9: FT-IR spectrum of Form B.
Figure 10: FT-IR spectrum of Form C.
Figure 11: FT-IR um of Form D.
Figure 12: FT-IR spectrum of Amorphous Form.
Figure 13: FT-IR spectrum of γ-CD inclusion complex.
Figure 14: Raman spectrum of Form A.
Figure 15: Raman spectrum of Form B.
Figure 16: Raman um of Form C.
Figure 17: Raman spectrum of Form E.
Figure 18: Raman spectrum of Amorphous Form.
Figure 19: Raman spectrum of γ-CD inclusion x.
Figure 20: Phase solubility diagram of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-
)methyl-isoxazolylmethoxy]-pyridinyl}-methanone and γ-CD.
The API solubility is shown in [µg/mL]. The solid phase in equilibrium with the saturated
solution was verified at selected points (arrows) by Raman and XRPD measurements to identify
and confirm potential state transformations, such as formation of polymorph B
(monohydrate) from the initially used polymorph A, or conversion of the free API to the γ-CD
inclusion complex.
Figure 21: Mean in vitro dissolution profiles in SGF
Mean in vitro dissolution profiles of micronized powders of Form A (○), Form B (▼), Form C
(■) and γ-CD inclusion x (∆) in SGF at room temperature. Measurements were performed
in triplicate (n=3).
Figure 22: Mean in vitro dissolution profiles in FeSSIF
Mean in vitro dissolution profiles of micronized powders of Form A (○), Form B (▼), Form C
(■) and γ-CD inclusion complex (∆) in FeSSIF at room temperature. Measurements were
performed in triplicate (n=3).
Figure 23:
Figure 23 shows ions of crystal habits.
Examples
The following examples 1 - 28 are provided for illustration of the claimed invention, which
relates to the solid form C, and also to illustrate other solid forms as described herein. They
should not be considered as limiting the scope of the invention, but merely as being
representative f.
Example 1: Preparation of crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous
polymorphic form A (Form A)
Form A can be prepared as described in .
Step a: (E)- and/or (Z)Fluoro-benzaldehyde oxime
To a suspension of robenzaldehyde (24.8 g, 200 mmol) (6.75 g, 54 mmol) and
hydroxylamine hloride (4.16 g, 60 mmol) in ethanol (4.3 mL) and water (13 mL) was
added ice (25 g). Then a solution of sodium hydroxide (5.5 g, 138 mmol) in water (6.5 mL) was
added dropwise within a 10 min period (temperature rises from -8 °C to + 7 °C) whereupon most
of the solid dissolves. After 30 min stirring at room temperature a white solid precipitated and
the resulting mixture was then diluted with water and acidified with HCl (4 N). The white
precipitate was then ed off, washed with water and dried under high vacuum to afford the
title compound (23.3 g, 84%) which was obtained as a white solid. MS: m/e = 139.1 [M]+.
Step b: (E)- and/or (Z)-N-Hydroxyfluoro-benzenecarboximidoyl chloride
To a solution of (E)- and/or (Z)fluoro-benzaldehyde oxime (23.3 g, 167 mmol) (6.9 g, 50
mmol) in DMF (50 mL) was added N-chlorosuccinimide (6.6 g, 50 mmol) portionwise over 1 h,
keeping the temperature below 35 °C. The reaction mixture was stirred at room temperature for 1
h. The mixture was then poured onto ice-water, and extracted with ethyl acetate. The combined
organic layers were then washed with water and brine, dried over sodium sulfate and evaporated
to afford the title nd (25.9 g, 89%) which was obtained as an off white solid. MS: m/e =
173.0 [M]+.
Step c: 3-(4-Fluoro-phenyl)methyl-isoxazolecarboxylic acid ethyl ester
To a solution of (E)- and/or (Z)-N-hydroxyfluoro-benzenecarboximidoyl chloride (15.4 g, 89
mmol) (11.1 g, 64 mmol) in diethylether (151 mL) was added ethyl noate (7.2 g, 7.5 mL,
64 mmol) at 0 °C followed by the dropwise addition of triethylamine (7.8 g, 10.7 mL, 77 mmol)
and the resulting mixture allowed to warm up to room temperature overnight. The mixture was
then poured onto ice-water, and extracted with diethylether. The combined organic layers were
then washed with water and brine, dried over sodium sulfate and evaporated. Purification by
chromatography (SiO2, heptane:ethyl acetate = 100:0 to 1:1) afforded the title compound (9.8 g,
44%) which was obtained as an off white solid. MS: m/e = 250.1 [M+H]+.
Step d: [3-(4-Fluoro-phenyl)methyl-isoxazolyl]-methanol
To a solution of 3-(4-fluoro-phenyl)methyl-isoxazolecarboxylic acid ethyl ester (3.0 g, 12
mmol) (6.18 g, 25 mmol) in THF (320 mL) was added portionwise lithiumaluminiumhydride
(528 mg, 14 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 3 h. The
mixture was then cooled to 0 °C and water (518 µL) added followed by sodium hydroxide (15%
solution, 518 µL) and then again water (1.5 mL) and the mixture then stirred ght at room
temperature. The precipitate was then filtered off and washed with THF. The combined washings
and te were then ated. Purification by tography (SiO2, heptane:ethyl acetate =
100:0 to 1:1) afforded the title compound (1.8 g, 71%) which was obtained as a white solid. MS:
m/e = 208.1 [M+H]+.
Step e: 4-Fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid methyl ester
To a suspension of sodium hydride (55% dispersion in mineral oil, 852 mg, 20 mmol) in THF
(27 mL) was added a solution of [3-(4-fluoro-phenyl)methyl-isoxazolyl]-methanol (103 mg,
0.55 mmol) (3.68 g, 18 mmol) in THF (54 mL) at 0 °C and the reaction mixture warmed to room
temperature over 30 min. Then a solution of methyl ronicotinate (3.35 g, 20 mmol) in THF
(1.5 mL) was added dropwise at 0 °C and the reaction mixture was stirred at room temperature
ght. The reaction mixture was then poured into aqueous sodium chloride (saturated) and
the mixture was extracted with ethyl acetate. The ed organic layers were then washed
with water and brine and then dried over sodium sulfate, filtered and evaporated. cation by
chromatography (SiO2, heptane:ethyl acetate = 7:3) afforded the title compound (81 mg, 47%)
which was obtained as a light yellow solid. MS: m/e = 343.3 [M+H]+.
Step f: 6-[3-(4-Fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid
To a solution of 6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid methyl
ester (1.4 g, 4.2 mmol) (538 mg, 1.1 mmol) in THF (5 mL) was added a solution of lithium
hydroxide monohydrate (94 mg, 2.2 mmol) in water (5 mL) and methanol (1 mL) added and the
resulting mixture stirred at room temperture overnight. The mixture was acidified to pH 4 with
HCl (25%, 3 drops) and methanol (2 drops) added. A gum began to form and the mixture was
cooled at 0 °C for 1.5 h and then the aqueous layer ed off. Trituration with diethylether
and hexane afforded the title compound (1.1 g, 78%) which was obtained as a white solid. MS:
m/e = 327.3 [M-H]-.
Step g: crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methylisoxazolylmethoxy
]-pyridinyl}-methanone in ous polymorphic form A (Form A)
To a solution of 4-fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid (99 mg,
0.33 mmol (69 mg, 0.2 mmol)) in DMF (300 µL) were added 2-(1H-benzotriazoleyl)-1,1,3,3-
tetramethyluronium tetrafluoroborate (71 mg, 0.22 mmol), N,N-diisopropyl ethyl amine (171 µL,
1.0 mmol) and thiomorpholine-S,S-dioxide (17.3 µL, 0.22 mmol). The resulting reaction mixture
was stirred for 1 h at room ature. Concentration and purification by chromatography
(SiO2, heptane:ethyl acetate = 100:0 to 1:1) afforded the title compound (73 mg, 55%) as a white
solid. MS: m/e = 446.1 [M+H]+.
Example 2: Preparation of Form A
A solution of 0.1 g of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)
methyl-isoxazolylmethoxy]-pyridinyl}-methanone in 0.7 mL of 2-pentanol or THF was
crash-cooled with liquid nitrogen, isolated by centrifugation at 25 °C and dried at 20 °C and
reduced pressure at <5 mbar for 2 d.
Example 3: ation of Form A
152.4 mg of 1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methylisoxazolylmethoxy
]-pyridinyl}-methanone were dissolved in 2.14 mL of 2-pentanol at 60
°C yielding a colorless solution. The t was ated slowly until dryness (perforated
cover foil, 5 d at ambient conditions) to yield blade-like crystals.
Example 4: Preparation of Form A
700.0 g of 4-fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid (Ex. 1
step f), 10 L of THF and 469.0 g of rbodiimidazol were stirred at ambient temperature for
one hour. 407.0 g of thiomorpholine-S,S-dioxide, 12.0 g of 4-dimethylaminopyridine und 340
mL of triethylamine p.a. were added successively and refluxed under stirring over two nights.
Additional 82.0 g of thiomorpholine-S,S-dioxide and 68.0 mL of triethylamine p.a. were added
and further refluxed under stirring overnight (o.n.). The experiment was cooled down to approx.
°C. 10 L of desalinated water and 16 L of ethanol were added successively. The emerging
solution was cooled down to 20 °C, seeded with 12 g of Form A and stirred at ambient
temperature for 30 min. The suspension was reduced to 16 L at max. 35 °C. In order to replace
THF, 20 L of ethanol were added. The suspension was stirred at ambient temperature o.n. and
then filtrated. The filter cake was rinsed with 7.4 L of a 1:1 desalinated water / ethanol mixture
and dried at 50 °C o.n. yielding 820 g of Form A (86 %).
e 5: Preparation of Form A
16.32 g of Form B were dissolved in 257 g THF at 50°C. To remove the water from the
on 172 g of THF were distilled off under d pressure at 80°C. Then this water free
product solution was cooled to room temperature.
Keeping the jacket temperature constant at -5°C, 238 g of heptane were circulated across a
hear-mixer device with a velocity of 20 l/h by use of a peristaltic pump. After 5 Minutes
the high-shear-mixer was started with a rotation rate of 15000 RPM to 24000 RPM and the
product solution from above was pumped with a flow rate of 1.6g/min ly h the
injector into the rotor-stator system. After addition was completed, the resulting crystals were
filtered and dried at 40°C at 30 mbar for 15 h to yield Form A.
Example 6: Preparation of Form A
100 g of Form B were dissolved in 1200 g THF at 50°C. About 50% of THF were distilled
off at 70°C under reduced pressure (800 mbar) to yield a 20% (w/w) solution of Form B in THF.
In a distillative solvent exchange, THF/water (of ion) was exchanged against dry THF at
800 mbar and at 70°C while keeping the solvent level constant until the water content was below
0.1% (w/w). 888g of heptane at 5°C as antisolvent were seeded with 1% (w/w) of Form A.
uently the product solution was cooled to 50°C and was dosed during 30 minutes using a
temperated hose eath suface to the heptane present at 5 °C. The resulting crystals were
filtered and dried at reduced pressure until constant weight to yield Form A (92%).
Example 7: Preparation of Form A
41g of Form B were dissolved in 170g THF at 50°C. 30 g of ethanol were added and the
solution cooled to 30°C. In a distillative solvent exchange, the solvent (THF/ethanol) was
exchanged to the anti-solvent ethanol at a temperature of 30°C and at reduced pressure (300
mbar) while the volume was kept nt by continuously replacing the distillate by a total of
340 g of ethanol. 20 minutes after start of the lation, crystallization was initiated by seeding
with 2% (w/w) of crysals of Form A. Subsequently the pressure was reduced to 230 mbar. 50
minutes after start of the distillation, the pressure was reduced to 130 mbar. 67 minutes after start
of the distillation, the solvent exchange was ted. The resulting suspension was stirred for
1.5 h at ambient temperature and subsequently filtered. The obtained ls were dried in a
vacuum dryer at 40°C over-night to yield 36.4 g of Form A (92.4%).
Example 8: Preparation of crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone monohydrate in
polymorphic form B (Form B)
Step a) (E)- and/or (Z)fluoro-benzaldehyde oxime
To a suspension of 4-fluoro-benzaldehyde (30.4 g, 0.24 mol) in water (50 mL) was added at 0-
°C within 5 minutes a solution of hydroxylamine hydrochloride (17.7 g, 0.25 mol) in water (30
mL) and the resulting mixture stirred for 15 minutes at 0-5°C. The mixture was then treated at
-25°C within 15 s with 32% NaOH (24.44 mL, 0.26 mol) and the ing suspension
was stirred for one additional hour and then extracted with ethyl acetate (3x100 mL). The
combined organic layers were washed with water (2x100 mL) and subsequently concentrated to
dryness to afford 31.9 g (95%) of the title oxime as a white solid.
Step b) 3-(4-Fluoro-phenyl)methyl-isoxazolecarboxylic acid ethyl ester
To a suspension of 4-fluoro-benzaldehyde oxime (1.39 g, 10.0 mmol) in DMF (10 mL) was
added portionwise within 5 s at 15 to 20°C N-chlorosuccinimide (1.36 g, 10.0 mmol) and
the resulting mixture was stirred at room ature for 90 minutes. The yellow on
(containing N-Hydroxyfluoro-benzenecarboximidoyl chloride) was then treated within 2
s at room temperature with a solution of ethyl(1-pyrrolidino)crotonate (1.89 g, 10.0
mmol) in 5 mL of DMF and the resulting solution was stirred at room temperature for 28 hours.
The mixture was diluted with water (25 mL) and subsequently extracted with ethyl acetate (4x25
mL). The combined organic layers were washed with 1 M HCl (2x25 mL) and water (2x25 mL),
dried over Na2SO4 and subsequently concentrated to dryness (45°C/25 mbar) to afford 2.37 g
(95%) of the title ester as a brownish solid with a purity of 100% (by GC) and 97% (by HPLC).
Step c) luoro-phenyl)methyl-isoxazolecarboxylic acid
A mixture of 179.5 g (0.72 mol) of 3-(4-Fluoro-phenyl)methyl-isoxazolecarboxylic acid
ethyl ester in 880 g of ethanol 95% was stirred at 20-30°C for 40 minutes and then treated with
78.5 g of solid sodium hydroxide. The resulting mixture was stirred for 5 h at 20-30°C. Ethanol
was d in vacuum at C and the residue was subsequently treated with 500 g of
water at C to afford a clear solution. The solution was stirred for 40 minutes and filtered.
To the filtrate was added 235 g of methyl utyl ether and 600 g of water and the resulting
mixture stirred for 20 min and then stood for 20 min. The layers were separated and the aqueous
layer was acidified to pH <1 with hydrochloric acid. The crystals were filtered and washed with
water to provide 147 g crude wet product. The crude wet product was suspended in 680 g of
toluene and the mixture was heated at 75-85 °C for 7 h. The mixture was cooled to C and
stirred for 1 hour at this temperature. The crystals were filtered off and dried at C in
vacuum over night to afford 137 g (86 % yield) of the title acid as a white to slightly yellow solid
with a purity of 99.9 % (HPLC).
Step d) [3-(4-Fluorophenyl)methyl-isoxazolyl]-methanol
A suspension of 448 g of tetrahydrofuran and 95 g (0.70 mol) of zinc chloride was stirred at 20-
30°C for 1 h. 23.6 g (0.62 mol) of sodium borohydride were added in portions at 20-38 °C and
the mixture uently stirred at 60-65°C for 3 h. A on of 69 g (0.31 mol) of luorophenyl
)methyl-isoxazolecarboxylic acid in 220 g THF was added dropwise and the
resulting mixture stirred at 60-65 °C for 16 h. The reaction was then quenched by the drop wise
on of mixture of 93 g of HCl in 202 g of water at 5-10°C. The mixture was stirred at this
ature for 2 h to dissolve the solids completely. The solvent was removed under reduced
pressure with a jacket temperature of 35-40°C. To the residue were added 510 g of water. The
resulting suspension was cooled to 20-30°C and the crystals were filtered off and washed with
water. The crude wet product was stirred for 1 h in a mixture of 150 g of water, 31 g of HCl and
419 g of MTBE. The lower aqueous phase was removed and organic phase was dried with 25 kg
of anhydrous sodium sulfate, stirred for 0.5 h and filtered under en. The filtrate was almost
completely concentrated under reduced pressure at 40-45°C. The residue was treated at 20-25°C
with 100 g of MTBE. The mixture was stirred at 55-60°C for 2 h, cooled to 0°C and
subsequently stirred at this temperature for onal 2 h. The crystals were filtered off and
dried at 45-50°C in vacuum over night to afford 42 g (66 % yield) of the title alcohol as an off-
white solid with a purity of 99.9% (HPLC).
Step e) 6-[3-(4-Fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinonitrile
To a suspension of sodium hydride (60% in mineral oil, 7.9 g, 181 mmol, 1.5 eq.) in THF (65
mL) was added within 30 minutes at room temperature a solution of [3-(4-Fluorophenyl)
methyl-isoxazolyl]-methanol (25.0 g, 121 mmol) and 6-chloronicotinonitrile (16.7 g, 121
mmol) in THF (120 mL) and the resulting e was stirred for one hour. A solution of citric
acid (18.5 g, 96.5 mmol) in water (185 mL) was added to the reaction mixture within 30 minutes.
From the resulting THF/water mixture THF was distilled off under reduced pressure at a jacket
temperature of 60°C and replaced by ethanol. In total 284 g of ethanol were added. The resulting
suspension was d for one hour at room temperature. The crystals were ed off, washed
with a mixture of ethanol (60 mL) and water (60 mL) and subsequently dried at 50°C/<25 mbar
to afford 36.5 g (91% corrected yield) of the title nitrile as an off-white solid with an assay of 93
%(w/w).
Step f) 6-[3-(4-Fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid
6-[3-(4-Fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinonitrile (58.8 g, 190 mmol) was
suspended in water (440 mL) and ethanol (600 mL) and treated with 32% sodium hydroxide
solution (178 mL 1.92 mol). The mixture was heated to 50-55°C and subsequently stirred at this
temperature for 15 hour. The slightly turbid mixture was polish filtered to remove the ether byproduct
6-[3-(4-Fluoro-phenyl)methyl-isoxazolylmethoxymethyl(4-fluoro-phenyl)
methyl-isoxazole. The first vessel and the transfer lines were rinsed with a mixture of water (50
mL) and ethanol (50 mL). The filtrate was treated at C within one hour with 25%
hydrochloric acid (approx. 280 mL) until the pH was <2.0. The resulting suspension was stirred
for one hour at room temperature. The crystals were filtered off, washed with a mixture of
ethanol (200 mL) and water (200 mL) and subsequently dried at 50°C/<25 mbar until constant
weight to afford 52.0 g (83%) of the title acid as an off-white solid with a purity of 99.5 %.
Step g) Purification of thiomorpholine-1,1-dioxide HCl
A mixture of 60 g of thiomorpholine-1,1-dioxide HCl in 600 mL THF, 105 mL water and 30 mL
DMF was heated to 63-66°C (slightly reflux) and the resulting clear to ly turbid solution
d at this temperature for 5 to 10 hours. The mixture was then treated at 63-66°C within 30
minutes with 300 mL of THF. The mixture was then cooled to 0-5°C within 3 hours and the
resulting suspension stirred at this ature for one additional hour. The ls were filtered
off, washed with THF (2x25 mL) and dried at 50°C and under reduced pressure (<20 mbar) to
afford 56.6 g (94%) of rpholine-1,1-dioxide HCl with a purity of 100 % (area) and a THF
content of 0.14%.
Step h) crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluoro-phenyl)methylisoxazolylmethoxy
]-pyridinyl}-methanone monohydrate in rphic form B (Form B)
6-[3-(4-Fluoro-phenyl)methyl-isoxazolylmethoxy]-nicotinic acid (23.0 g, 70.1 mmol) and
1,1-carbonyldiimidazole (15.3 g, 94.6 mol, 1.35 eq.) were dissolved in THF (120 mL) and the
resulting solution was stirred for one hour at room temperature. This solution was then added to
a suspension of thiomorpholine-1,1-dioxide HCl (16.9 g, 98.5 mmol), DMAP (400 mg, 3.27
mmol) and triethylamine (9.78 g, 96.7 mmol) in THF (120 mL). The resulting mixture was
heated to reflux temperature and subsequently stirred at this temperature for 50 hours. The
mixture was cooled to room temperature and then d within one hour with water (300 mL).
From the resulting suspension THF was distilled off under reduced pressure and with a jacket
temperature of 60°C and continuously replaced by l (426 g) at constant volume. The
sion was cooled to room temperature and d for 2 hours. The crystals were filtered off,
washed with a mixture of ethanol (100 mL) and water (100 mL) and subsequently dried at
mbar until constant weight to afford 28.9 g (92%) of Form B as a colorless solid with
purity of 99.7% (area) as measured by HPLC.
Example 9: Preparation of Form B
Form A was aged for 8 days in an aqueous suspension. Isolation by filtration yielded
crystalline blades which were rinsed with water and then dried at ambient ions.
Example 10: Preparation of Form B
155.9 mg of Form A were dissolved in 2.2 mL of 15% water in acetone at 60 °C yielding a
colorless solution. The solvent was evaporated slowly until dryness (perforated cover foil, 5 d at
ambient conditions) to yield equant crystals.
Example 11: Preparation of Form B
509 mg of Form A were dissolved in 7.1 mL 15 %-vol. water/acetone at 60 °C yielding a
colorless on. Then the solvent was allowed to evaporate slowly over 8 days (perforated
cover foil, ambient ions). The residue was dried at 20 °C/<5 mbar o.n. (vacuum tray dryer),
yielding 440 mg (86 %) of equant ls.
Example 12: Preparation of Form B
.0 g of Form C were dissolved in 50 mL of THF and 17 mL of DMF under stirring at
ambient temperature. During a period of 30 minutes, the solution was gradually heated to 50-
55°C and stirred at this temperature for 15 minutes. 75 mL of water were added dropwise during
2-3 hours under stirring at 50-55°C. The resulting suspension was stirred for additional 15
minutes at 50-55°C and afterwards gradually cooled to 15-20°C during 2-4 hours. The
suspension was stirred for 5 hours at 15-20°C, filtered and washed with a small amount of water.
The obtained crystals were dried for 12 hours at 40°C at reduced pressure (20mbar) yielding
Form B (95%).
e 13: Preparation of crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous
polymorphic form C (Form C)
4.5 kg of Form A were dissolved in 40 L of THF at ambient temperature. After polishing
filtration the filter was rinsed by 5 L of THF. From the combined solutions solvent was distilled
off at d pressure at a temperature below 70 °C while the volume was kept constant by
uously ing the distillate by a total of 90 L of l. The suspension was allowed to
cool to ambient temperature over 12 hours. 25 L of ethanol were added, the suspension was
heated to 78°C at ambient pressure, d to cool to ambient temperature over 12 hours and
stirred for one additional hour. Crystallization at ambient pressure occurred at 78°Cto 70°C. 25 L
of ethanol were distilled off at reduced pressure at 35-40°C and the suspension was allowed to
cool to ambient temperature over 12 hours. The product was isolated by filtration and rinsed by
L of ethanol. The ls were dried in a vacuum tray dryer (50 °C/5 mbar for 3 d), yielding
4.1 kg (91%) colorless like crystals. It was possible to reproduce the experiment on 10 g
scale.
Example 14: Preparation of Form C
200 mg of Form A were stirred in 0.8 mL of ethyl acetate at ambient temperature for 14
days (suspension). After isolation of the solids by filtration and drying in a vacuum tray dryer
(50 °C/<5 mbar for 12 h) Form C was obtained. Alternatively, ethanol or toluene can be used
instead of ethyl acetate.
Example 15: Preparation of Form C
41g of Form B were dissolved in 170g THF at 50°C. 30g of ethanol were added and the
solution cooled to 30°C. In a distillative solvent exchange, the t (THF/ethanol) was
exchanged to the anti-solvent ethanol at a temperature of 30°C and at reduced pressure (300
mbar) while the volume was kept constant by continuously replacing the distillate by a total of
340g of ethanol. 20 minutes after start of the distillation, the pressure was reduced to 230 mbar.
s after start of the distillation, the previously clear yellow solution became opaque.
Two minutes later the opaque solution had turned into a thick suspension. 50 minutes after start
of the distillation, the pressure was reduced to 130 mbar. 68 minutes after start of the distillation,
the solvent exchange was completed. The resulting sion was stirred for 2h at ambient
temperature and uently filtered. The obtained crystals were dried in a vacuum dryer at
40°C over-night to yield 35.8 g of Form C.
e 16: Preparation of Form C
10g of Form B (22.4 mmol) were dissolved in 350 mL THF under stirring at ambient
temperature, filtered and the filter rinsed with 40mL of THF. In a lative solvent exchange,
the t of the filtrate was exchanged to l at a temperature of 60°C and at reduced
pressure (100-300 mbar) while the volume was kept constant by continuously replacing the
distillate by a total of 200 mL of ethanol. Crystallization was initiated after on of the first
20ml of ethanol by seeding with crystals of Form C. The resulting suspension was stirred for 1h
at ambient temperature, subsequently filtered and rinsed with 50mL of ethanol. The obtained
crystals were dried in a vacuum dryer at 50°C over-night to yield 8.8 g (88%) of Form C.
Example 17: Preparation of Form C
82g (177 mmol) of Form B were dissolved in 340 g of THF at 50°C. 60 g of ethanol were
added to prepare a 17%(w/w) solution of Form B in a THF/ethanol mixture of (85:15 (w/w). The
clear solution was allowed to cool to 35°C under stirring. A 10%(w/w) seeding suspension of 0.8
g of Form C suspended in 7.2g of a 50:50 (w/w) THF/ethanol mixture /w) Form C in
respect of final theoretical yield) was added and the reaction mixture was stirred for 30 min at
ambient temperature. The pressure was decreased to 300 mbar while the temperature was
increased to 50°C. In a distillative solvent exchange, the volume was kept constant by
uously replacing the distillate by a total 680 g of ethanol, which were added linearly (5.6
g/min) during a total time of 120 minutes. The reaction re is lowered, after 20 minutes of
ethanol addition to 230 mbar, and after 50 minutes of total ethanol addition to 130 mbar. After
115 minutes of ethanol addition, the ature was gradually lowered to 5°C during at a
cooling speed of 1 °C/min (30 min cooling time). The suspension was stirred for 30 minutes at 5
°C, filtered and rinsed with 68 g of ethanol. The ed crystals were dried at 40°C at 30 mbar
for 16h to yield 98.5 % of Form C.
Alternatively, this ation can be performed with acetone as solvent instead of THF.
Alternatively, this ation can be performed with isopropanol and/or n-heptane as antisolvent
instead of ethanol.
Example 18: Preparation of Form C
16.32 g of Form B were dissolved in 257 g THF at 50°C. To remove the water from the
solution 172 g of THF were distilled off under reduced pressure at 80°C. Then this water free
product solution was cooled to room temperature.
To 238 g Heptane at a temperature of -5°C 1.6 g (10 %(w/w) in respect of final theoretical
yield) of Form C were added under stirring as seeding material. g the jacket temperature
constant at -5°C, the ing suspension was circulated across a high-shear-mixer device with a
velocity of 20 l/h by use of a peristaltic pump. After 5 minutes the high-shear-mixer was started
with a rotation rate of 15000 RPM to 24000 RPM and the product solution from above was
pumped with a flow rate of 1.6g/min. directly h the or into the rotor-stator system.
After addition was completed, the ing crystals were filtered and dried at 40°C at 30 mbar
for 15 h to yield 91% of Form C with an average particle size d50 <10µm.
When conducting e 18 without seeds, Form A was ed (see Example 5).
Using 2%(w/w) Form C seeds, a mixture from Form A ant) and C was obtained.
Employing 5%(w/w) Form C seeds, a mixture from Form C (dominant) and A was obtained.
e 19: Preparation of Form C
14.12 g of Form B were dissolved in 240 g THF at 50°C. To remove the water from the
solution 160g of THF were distilled off under reduced pressure at 80°C. The water free solution
was cooled during 15 minutes to 25°C and 0.07 g Form C seeds (0.5%(w/w) in respect of final
theoretical yield) were added. After 30 minutes of stirring the temperature was lowered over 135
minutes to 15°C and 9.0 g heptane were added in parallel. The resulting suspension was stirred
for 30 minutes, then the ature was raised over 15 minutes to 35 °C. After 30 minutes the
temperature is cooled again over 165 minutes to 15°C and r 11 g of heptane were added in
parallel. After 30 minutes of stirring the temperature was raised again to 35 °C and the
suspension was stirred again for 30 minutes. Afterwards the temperature was lowered again to
15°C during 495 minutes and 33 g heptane were added in parallel. The resulting final sion
was stirred for additional 120 minutes, then filtered, dried at 40°C and 30 mbar for 16 hours to
yield 94 % of Form C with an average particle size d50 >50µm.
Example 20: Preparation of crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone trifluoroethanol
mono-solvate in polymorphic form D (Form D)
40 mg of Form A was equilibrated in 400 µl 3:1 trifluoroethanol/methanol (TFE/MeOH)
mixture for 7 days at room temperature by head-over-head rotation with magnetic stir bars in 2
mL HPLC glass crimp vials. After equilibration the solid phase was separated from the liquid
phase by centrifugation. The solvent was removed by a pipette and by strips of filter paper. The
residual solids were dried at 40°C in a vacuum tray dryer to 10 h at 20 mbar.
Example 21: Preparation of Form D
2 g of Form A were dissolved in 20 mL of a 3:1 trifluoroethanol/methanol mixture. Seed
crystals of Form D were added and the mixture was stored closed at ambient temperature for 3
days. The residual column-shaped crystals were isolated by filtration (glass filter) and dried in a
vacuum tray dryer (ambient temperature/20 mbar for 24 h).
Example 22: Preparation of crystalline (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous
polymorphic form E (Form E)
50 mg of Form B was subjected to dehydration/hydration cycles. At <5 %rH reversible
transformation into Form E was ed by means of Humidity Controlled XRPD.
e 23: Preparation of Form E
50 mg of Form B was placed into a desiccator, where the sample was dried over
concentrated ic acid for 36 h at ambient ature.
Example 24: ation of amorphous (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone (Amorphous
Form)
0.554 g of Form C was dissolved in 4.0 mL of dichloromethane in a round bottom flask.
The clear solution was rapidly concentrated using a rotary evaporator (40 °C e temperature,
vacuum stepwise reduced to 14 mbar). The residue was dried in a vacuum tray dryer (50 °C/<5
mbar for 2 days), yielding 0.498 g (90 %) of a colorless powder.
Example 25: Preparation of Amorphous Form
150 mg of Form A were molten at 160 °C in a glass vial using a heat gun and cooled to
ambient temperature to yield amorphous material.
Example 26: Preparation of 1:1 inclusion complex of (1,1-dioxo-1λ6-thiomorpholin
yl)-{6-[3-(4-fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone with
odextrin (γ-CD inclusion complex)
300 mg of Form A was weighed into a 20 mL screw cap glass vial. 6 mL deionized water
and γ-CD at a molar ratio of 1:2 was added. The suspension was equilibrated at room
temperature for 32 days by head-over-head rotation using a Heidolph Reax 2 mixer (VWR
International AG, Dietikon, Switzerland). Solid liquid separation was performed with amicon
Ultrafree-MC® centrifugal filter devices (0.45 µm Durapore PVDF membrane, Millipore,
Bedford, MA) to yield crystals of the γ-CD inclusion complex.
e 27: Phase Solubility Analysis
Phase solubility diagrams are used to characterize complex formation between two
compounds and represent the lity of the API as a function of the cyclodextrin
concentration. The phase lity diagram of (1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-
fluoro-phenyl)methyl-isoxazolylmethoxy]-pyridinyl}-methanone with γ-cyclodextrin
showed BS-type behavior according to the fication of Higuchi [T. Higuchi et al., Adv. Anal.
Chem. Instrum. (1965) 4:117-212] and Brewster [M. E. Brewster et al. Adv. Drug Delivery Rev.
(2007) 59:645-666] (figure 20). The API concentration first increased with increasing
cyclodextrin concentration due to the complexation of the API with cyclodextrin molecules.
After an initial increase in drug solubility, the m solubility of the complex was reached
and the complex started to precipitate, indicating the formation of a less soluble inclusion
complex (γ-CD inclusion complex). At the end of the plateau, the entire solid API has been
consumed and further addition of API would result in ion of API in the solution by
complex formation and concomitant precipitation of the insoluble complex. 150 mM represents
the solubility limit of γ-cyclodextrin in aqueous solution.
The binding constant (K) of the γ-CD inclusion complex was calculated from the initial
straight line portion of the phase solubility diagram by linear regression, according to the
following equation [T. Higuchi et al., Adv. Anal. Chem. Instrum. (1965) 4:117-212]:
slope .0 00131
K = = M− =1 5 4.10 M−1 (Eq. 1)
intercept × (1− slope) .0 00000257× 1( − .0 00131)
The g constant of the γ-CD inclusion x calculated according to equation (1)
was 510.4 M-1. The binding constant (K) is a measure of the affinity of the API to enter the
relatively apolar cavity of the CD. The desired situation is to have ient ty, such as to
enhance the concentration of total dissolved drug, but still allow for dissociation of the x
followed by absorption of the API. A binding constant of 510.4 M-1 in case of the γ-CD inclusion
complex is in a good range and suggests that an oral solid dosage form with an increased
dissolution rate should be feasible.
Example 28: in vitro Dissolution s
The in vitro dissolution studies med in this work were conducted in a miniaturized
system with 100 mL dissolution medium per experiment. In comparison to the 1000 mL vessels
of the conventional USP apparatus the experimental set-up that was used here was scaled-down
and simplified (magnetic stirring instead of paddles, room ature instead of 37 °C). The
dissolution experiments were performed under non-sink ions (drug concentration >10% of
the solubility value). Simulated gastric fluid (SGF) was prepared with 2 g/L NaCl and 1 g/L
Triton® X-100 in 0.1 N HCl. The ing measured pH of SGF was 1.2. ted fed state
intestinal fluid (FeSSIF) was prepared as previously reported in Galia E. et al. (Pharm. Res.
(1996) 13:S-262) and contained 15 mM sodium taurocholate, 3.75 mM lecithin and had a pH 5.0.
Oral absorption of a drug compound from a solid dosage form is dependent on dissolution
rate and solubility. In the present work the in vitro ution of the γ-CD inclusion complex
was compared to micronized powders of polymorph Form A, Form B and Form C. Figure 21
presents the dissolution profiles measured in simulated gastric fluid (SGF) and Figure 22 shows
the dissolution profiles in simulated fed state intestinal fluid (FeSSIF). In both dissolution media
the γ-CD inclusion complex behaves completely different compared to micronized powders of
polymorph Form A, Form B and Form C. The γ-CD inclusion complex ed a much higher
initial concentration in SGF and FeSSIF which rapidly dropped in the first 60 min to a level
which was comparable to polymorph C values. In case of the micronized powders of polymorphs
the saturation solubility of the specific polymorphs was vely rapidly achieved (≤ 30 min)
and the dissolved drug contents remained ged until the end of the experiment (180 min).
Changes of pH values in the dissolution test samples taken at different time points were not
observed. The ranking of the different solid forms with respect to dissolution speed and
maximum drug concentration achieved was identical in both media. The differences in the
ution profiles in SGF and FeSSIF can be explained by the different composition of the two
media since the dissolution generally depends on a variety of factors such as pH, tant,
buffer ty, ionic strength, etc. The ability of the γ-CD ion complex to form a
supersaturated on presents promising opportunities to increase the in vivo absorption and
oral ilability compared to the crystalline pure phases of Form A, Form B and Form C.
To maintain the supersaturation promoted by the γ-CD inclusion complex the addition of
specific precipitation inhibitors such as hydroxypropyl methylcellulose (HPMC),
polyvinylpyrrolidone (PVP), etc. to the final dosage form can be beneficial. A prolongation of
the supersaturated state can dramatically impact and improve in vivo absorption and
bioavailability.
Claims (3)
- Claims 1. A solid form of a compound of formula (I) N S N O F (I), 5 wherein the solid form is crystalline 1,1-dioxo-1λ6-thiomorpholinyl)-{6-[3-(4-fluorophenyl )methyl-isoxazolylmethoxy]-pyridinyl}-methanone in anhydrous polymorphic form C, characterized by an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta (CuKα) of 11.7°±0.2°, 17.4°±0.2°, 23.4°±0.2°.
- 2. Crystalline polymorphic form C according to claim 1, characterized by an XRPD diffraction 10 n comprising XRPD peaks at angles of diffraction 2Theta (CuKα) of 10.5°±0.2°, 11.7°±0.2°, 14.2°±0.2°, 16.3°±0.2°, 16.7°±0.2°, 17.4°±0.2°, 17.9°±0.2°, 19.3°±0.2°, 23.4°±0.2°, 24.7°±0.2°, 25.1°±0.2°, 25.9°±0.2°.
- 3. Crystalline polymorphic form C according to claim 1, characterized by a g point with onset temperature (DSC) in the range of about 146 °C to 150 °C. 15 4. lline polymorphic form C according to claim 1, characterized by the XRPD diffraction pattern of figure 3. 5. A solid form of a compound of formula (I) according to any of claims 1 to 4, wherein the solid form is present in the ied solid form in a purity of at least 90% (w/w). 6. A lative solvent exchange process for the preparation of a solid form of a compound of 20 formula (I) according to any of claims 1 to 5 comprising: a) dissolution of the educt solid form in a solvent; b) distillation of the solvent while keeping the reactor liquid level constant by replacing the distillate by an antisolvent; c) physical separation of the d solid form from the suspension; n the solvent employed in step a) is selected from THF, DMF or acetone or a mixture thereof; wherein the antisolvent employed in step b) is selected from ethanol, iso-propanol, or nheptane or a mixture thereof; and 5 wherein step b) is performed at 50-80°C. 7. A hear process for the preparation of a solid form of compounds of formula (I) according to any of claims 1 to 5 sing: d) injection of a solution of the educt solid form in a t into a hear mixer comprising an antisolvent; 10 e) agitation of the rotor-stator system of the high-shear mixer; f) physical separation of the desired solid form from the suspension; wherein the solvent employed in step d) is selected from THF, DMF or acetone or a mixture thereof; wherein the antisolvent employed in step d) is ed from ethanol, iso-propanol, or n- 15 heptane or a mixture thereof; wherein the antisolvent of step d) comprises 5-10%(w/w) (in respect of final yield) of seeding particles of the desired solid form; and wherein steps d) and e) are performed at -20°C to 0°C". 8. Crystalline polymorphic form C according to any of claims 1 to 6, obtained by the process 20 of claim 6 or claim 7. 9. Pharmaceutical compositions sing a solid crystalline form of a compound of formula (I) according to any of claims 1 to 5 and a pharmaceutically acceptable excipient. 10. A solid form of a compound of formula (I) according to any of claims 1 to 5 for use as therapeutically active substances. 25 11. A solid form of a compound of formula (I) ing to any of claims 1 to 5 for the treatment or prevention of acute and/or c neurological disorders, ive disorders, Alzheimer’s disease, memory deficits, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, bipolar disorders, autism, Down syndrome, neurofibromatosis type I, sleep disorders, disorders of circadian rhythms, amyotrophic 30 lateral sclerosis (ALS), dementia caused by AIDS, psychotic disorders, substance-induced psychotic er, anxiety disorders, generalized anxiety disorder, panic disorder, onal disorder, obsessive/compulsive disorders, acute stress disorder, drug addictions, movement disorders, Parkinson’s disease, restless leg syndrome, cognition deficiency disorders, multi-infarct dementia, mood disorders, depression, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, neuropathic pain, stroke, Multiple sis (MS), acute Meningitis, Fetal Alcohol Syndrome, and attentional disorders, for 5 stroke recovery therapy, or for use as cognitive enhancers. 12. The use of a solid form of a compound of formula (I) according to any of claims 1 to 5 for the preparation of medicaments useful for the treatment or prevention of acute and/or chronic neurological ers, cognitive disorders, mer’s disease, memory deficits, schizophrenia, ve, negative and/or cognitive symptoms associated with schizophrenia, 10 bipolar ers, autism, Down syndrome, neurofibromatosis type I, sleep ers, ers of circadian rhythms, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, psychotic disorders, substance-induced psychotic disorder, anxiety disorders, generalized anxiety disorder, panic disorder, delusional disorder, obsessive/compulsive disorders, acute stress disorder, drug addictions, nt disorders, Parkinson’s disease, 15 restless leg syndrome, cognition deficiency disorders, multi-infarct dementia, mood disorders, depression, sychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, neuropathic pain, stroke, Multiple Sclerosis (MS), acute Meningitis, Fetal Alcohol Syndrome, and attentional disorders or for cognition enhancement. 13. A solid form of a compound of formula (I) according to claim 1, ntially as herein 20 described with reference to any example thereof. 14. A distillate solvent ge process ing to claim 6 substantially as herein described with reference to any example thereof. 15. A high-shear process according to claim 7 substantially as herein described with reference to any example thereof. 1 of 23
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11185993 | 2011-10-20 | ||
EP11185993.0 | 2011-10-20 | ||
PCT/EP2012/070522 WO2013057124A1 (en) | 2011-10-20 | 2012-10-17 | Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ622215A NZ622215A (en) | 2016-06-24 |
NZ622215B2 true NZ622215B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220267299A1 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
US9550767B2 (en) | Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate | |
KR20080044841A (en) | POLYMORPHIC FORMS OF IMATINIB MESYLATE AND PROCESSES FOR PREPARATION OF NOVEL CRYSTALLINE FORMS AS WELL AS AMORPHOUS AND FORM alpha; | |
TW202110811A (en) | Crystalline forms of a btk inhibitor | |
BR112020006239A2 (en) | composed of griseofulvin and pharmaceutical use thereof | |
US8975397B2 (en) | Solid forms | |
JP2016512516A (en) | Solid forms of quinazoline derivatives and their use as BRAF inhibitors | |
JP2022519301A (en) | N- (Pyridine-2-yl) Pyridine-Sulfonamide Derivatives and Their Use in the Treatment of Diseases | |
WO2012147832A1 (en) | Phenyl pyrrole derivative crystal | |
TWI662031B (en) | Crystals of 1- {2-fluoro-4- [5- (4-isobutylphenyl) -1,2,4-oxadiazol-3-yl] -benzylpyrene-3-azetidinecarboxylic acid type | |
WO2023284159A1 (en) | Compound containing sulfamide structure, and preparation method therefor and application thereof, and pharmaceutical composition and application | |
NZ622215B2 (en) | Solid forms of (1,1-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone | |
TW202035388A (en) | Crystalline forms of a lta4h inhibitor | |
US20200283381A1 (en) | Solid state forms of elafibranor | |
WO2024067542A1 (en) | Spirocyclic derivative-containing salt or crystal form, and preparation method therefor and use thereof | |
JP2022515196A (en) | Aminopyrimidine compounds for inhibiting protein kinase activity |